Bicyclic PRMT5 inhibitors

CN118946567APending Publication Date: 2024-11-12TYK MEDICINES ZHENGZHOU INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029718.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-08
Filing Date
2023-09-08
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing technologies are difficult to effectively inhibit PRMT5 activity, especially in MTAP-deficient cells, and the inhibitory effect on normal cells is insufficient, resulting in a low therapeutic index.

Method used

A bicyclic compound was developed. Through structural optimization, a compound with excellent PRMT5 selective inhibitory activity was obtained. It can effectively inhibit PRMT5 at high MTA concentrations and has a high inhibitory effect on MTAP-deficient cells.

Benefits of technology

It achieves effective inhibition of PRMT5 in MTAP-deficient cells, significantly improves the therapeutic index, and ensures safety and efficiency on normal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118946567A_ABST
    Figure CN118946567A_ABST
Patent Text Reader

Abstract

The invention provides a bicyclic PRMT5 inhibitor which is a compound with a structure as shown in a formula (I), and also provides a preparation method of the compound and application of the compound in regulation of PRMT5 activity or treatment of PRMT5 related diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Bicyclic PRMT5 inhibitors Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to bicyclic compounds used as PRMT5 inhibitors, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds and salts, and uses thereof, as well as their applications in regulating PRMT5 activity or treating PRMT5-related diseases. Background Art

[0002] Protein arginine N-methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the ω-nitrogen of the guanidino function of L-arginine residues in proteins (ω-monomethylation) and the transfer of a second methyl group to the other ω-nitrogen, generating symmetric dimethylarginine (sDMA). PRMT5 forms a complex with MEP50 (methylosome protein 50), which is required for substrate recognition and orientation and is also required for the histone 2A and histone 4 methyltransferase activities catalyzed by PRMT5 (e.g., see Ho et al. (2013) PLOS ONE 8(8):10.1371 / annotation / e6b5348e-9052-44ab-8f06-90d01dc88fc2).

[0003] Methionine adenosyltransferase (MAT), also known as S-adenosylmethionine synthetase, is an enzyme that catalyzes the reaction of methionine (Met) with ATP to produce S-adenosylmethionine (SAM). SAM serves as the primary methyl donor for methyltransferases in vivo, regulating gene expression, transcription, and translation through transmethylation reactions, thereby significantly influencing cell growth, cell death, and differentiation. Protein arginine N-methyltransferase 5 is a methyltransferase that uses SAM as a substrate and plays a crucial role in regulating tumor cell proliferation and other aspects.

[0004] Homozygous deletion of tumor suppressor genes is a key driver of cancer and frequently results in the collateral loss of passenger genes located near the tumor suppressor. Deletion of these passenger genes could yield therapeutic benefits, particularly in tumor cells. Homozygous deletion of the chromosome 9p2I locus, encompassing the well-known tumor suppressor CDKN2A (cyclin-dependent kinase inhibitor 2A), occurs in 15% of tumors and frequently includes the passenger gene MTAP (methylthioadenosine phosphorylase), a key enzyme in the methionine and adenine salvage pathways. MTAP loss leads to accumulation of its substrate, methylthioadenosine (MTA). MTA shares close structural similarity with the methyl donor S-adenosylmethionine (SAM), a substrate for the type II methyltransferase PRMT5. MTAP loss results in elevated MTA levels, which selectively compete with SAM for PRMT5 binding, rendering the methyltransferase in a hypoactive state and susceptible to further inhibition by PRMT5 inhibitors. Multiple genome-scale shRNA dropout screens performed on a large panel of tumor cell lines revealed a strong correlation between MTAP loss and cell line dependence on PRMT5. However, PRMT5 is a known cellular essential gene, and PRMT5 knockout and siRNA knockdown studies have shown that inhibition of PRMT5 in normal tissues (such as pan-cytopenia, infertility, skeletal muscle loss, cardiac hypertrophy, etc.) may be associated with significant side effects. Therefore, new strategies are needed to exploit this metabolic vulnerability and preferentially target PRMT5 in MTAP-deficient tumors while sparing PRMT5 in normal tissues (MTAP WT). Targeting PRMT5 with MTAP-synergistic small molecule inhibitors can preferentially target the MTA-bound state of PRMT5 enriched in MTAP-deficient tumor cells, while providing a higher therapeutic index than normal cells with normal MTAP and lower MTA levels.

[0005] Therefore, the development of new MTA-synergistic PRMT5 inhibitors that can better inhibit PRMT5 activity under elevated MTA concentrations, especially in MTAP-deficient cells, has broad application prospects.

[0006] Summary of the Invention

[0007] The object of the present invention is to provide a compound represented by formula (I), a preparation method thereof, and use thereof as a PRMT5 inhibitor drug.

[0008] The first aspect of the present invention provides a compound, which is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof,

[0009] in:

[0010] R is selected from the following group: H, -NH2, C 1-3 Alkyl, -OC 1-3 Alkyl, C 1-3 Fluorinated alkyl, -OC 1-3 Fluorinated alkyl;

[0011] R1 is selected from the following groups: substituted or unsubstituted: monocyclic group A, bicyclic group B; the monocyclic group A is selected from the following group: C 3-8 Cycloalkyl, C 5-8 Aryl, 3-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, 5-8 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S; the bicyclic group B is selected from the following group: C 5-12 Cycloalkyl, C 8-12 aryl, 5-12 membered heterocyclic radical containing 1-4 heteroatoms selected from N, O or S, 8-12 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S; wherein, when substituted, the substitutions are each independently replaced by R a1 replace;

[0012] R2 is selected from the group consisting of H, halogen, -CN, C 1-6 Alkyl, -OR a2 ; or R2 together with the C to which it is connected forms C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S; wherein the alkyl, cycloalkyl, heterocycloalkyl is optionally substituted by a substituent selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, C 1-3 Fluoroalkoxy, C 3-5 Cycloalkyl, 4-6 membered heterocycloalkyl containing 1-2 heteroatoms selected from N, O or S;

[0013] Each R3 is independently selected from the group consisting of H, deuterium, =O, halogen, -CN, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, -OR a3 、-N(R a3 ) 2, wherein the alkyl, heteroalkyl is optionally substituted by a substituent selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, C 1-3 Fluoroalkoxy;

[0014] Alternatively, two R3's and the atoms to which they are attached, or R3's and the group attached to the nitrogen heterocycle to which they are attached, together form a 3-10 membered carbocyclic or heterocyclic ring, and the carbocyclic or heterocyclic ring and the nitrogen heterocycle form a bridged ring, a fused ring, or a spirocyclic ring;

[0015] R4 is selected from the group consisting of H, deuterium, halogen, -CN, C 1-3 Alkyl, C 2-6 Alkynyl, C 3-5 Cycloalkyl, 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S, -OR a4 、-C(=O)N(R a4 )2、-S(=O)2N(R a4 ) 2, wherein the alkyl, cycloalkyl, heterocycloalkyl is optionally substituted by a group selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Fluorinated alkyl;

[0016] R5 is selected from the group consisting of H, deuterium, halogen, -CN, C 1-3 Alkyl, C 3-5 Cycloalkyl, 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S, -OR a5 , wherein the alkyl, cycloalkyl, heterocycloalkyl is optionally substituted by a group selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Fluorinated alkyl;

[0017] Each x1, x2, x3, x4 is independently selected from the following group: O, C(R a6 ) m 、N(R a6 ) m ;

[0018] Each R a2 、R a3 、R a4 、R a5 Independently selected from the group consisting of H, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-7 membered heterocyclic group containing 1-2 heteroatoms selected from N, O or S, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclic group is optionally substituted by 1, 2 or 3 R b1 replace;

[0019] Each R b1 Independently selected from the group consisting of: =O, halogen, -CN, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S1-6 Heteroalkyl, C 1-6 Haloalkyl, -OR c1 、-N(R c1 )2;

[0020] Each R c1 Independently selected from the group consisting of H, C 1-6 Alkyl, C 3-6 Cycloalkyl;

[0021] Each R a1 Independently selected from the group consisting of deuterium, halogen, -CN, =O, -OH, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 1-6 Haloalkyl, -LC 3-9 Cycloalkyl, -L-(saturated or partially saturated 3-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S), -LC 6-10 Aryl, -L- (5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S), -OL- (3-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S), -OR b2 、-N(R b2 )2、-LN(R b2 )2, -C(=O)R b2 、-C(=O)OR b2 、-P(=O)(R b2 )2、-NR b2 C(=O)R b2 、-NR b2 C(=O)OR b2 、-C(=O)N(R b2 )2、-OC(=O)N(R b2 )2、-S(=O)R b2 、-S(=O)2R b2 、-SR b2 、-S(=O)(=NR b2 )R b2 、-NR b2 S(=O)2R b2 、-S(=O)2N(R b2 ) 2, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by a substituent selected from the group consisting of: =O, deuterium, halogen, -CN, -OH, -NH2, -NHC 1-3 Alkyl, -N(C 1-3 Alkyl)2, C 1-6 Alkyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, -OC 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, -OC 1-6 Halogenated alkyl, C 1-6 Haloalkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Haloheteroalkyl, -C(=O)Me, -C(=O)NHMe, -NHC(=O)Me;

[0022] Each R b2 Independently selected from the group consisting of H, C 1-6 Alkyl, C 1-6 Haloalkyl, C substituted with 0-1 =O and containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 3-9 Cycloalkyl, 3-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O or S, optionally substituted by =O or -CH3;

[0023] Each L is independently a bond or C 1-6 Alkylene, wherein the C 1-6 The alkylene group is optionally substituted with a substituent selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, C 1-3 Fluoroalkoxy;

[0024] Each R a6 Independently selected from the group consisting of H, deuterium, halogen, -CN, C 1-3 Alkyl, C 1-3 Fluorinated alkyl, C 1-3 Alkoxy, C 1-3 Fluoroalkoxy;

[0025] Each m is independently selected from the following group: 0, 1, 2;

[0026] n is selected from the following group: 0, 1, 2, 3.

[0027] In another preferred embodiment, the formula Having a structure selected from the group consisting of:

[0028] wherein R1, R2, R3, x4, and n are as defined in claim 1.

[0029] In another preferred embodiment, x4 is C(R a6 ) m , preferably CH2.

[0030] In another preferred embodiment, the formula Having a structure selected from the group consisting of:

[0031] wherein R1, R2, R3, and n are as defined above.

[0032] In another preferred embodiment, x4 is O.

[0033] In another preferred embodiment, the formula Having a structure selected from the group consisting of:

[0034] wherein R1, R2, R3, and n are as defined above.

[0035] In another preferred embodiment, x4 is N(R a6 ) m , preferably NCH3.

[0036] In another preferred embodiment, the formula Having a structure selected from the group consisting of:

[0037] wherein R1, R2, R3, and n are as defined above.

[0038] In another preferred embodiment, the compound has a structure selected from the group consisting of:

[0039] wherein R1, R2, R3, R4, R5, x1, x2, x3, x4, R, and n are as defined in claim 1.

[0040] In another preferred embodiment, the compound has a structure selected from the group consisting of:

[0041] wherein R1, R2, R3, R4, and x2 are as defined in claim 1.

[0042] In another preferred embodiment, R1 is selected from substituted or unsubstituted bicyclic group B, wherein, when substituted, the substitutions are each independently R a1 replace;

[0043] The compound has a structure selected from the group consisting of:

[0044] Among them, R2, R3, R4, R a1 , x2 as defined in claim 1.

[0045] In another preferred embodiment, the monocyclic group A has a structure selected from the following group:

[0046] The bicyclic group B has a structure selected from the group consisting of:

[0047] In another preferred embodiment, R1 is composed of 0-3 R a1 Independently replaced

[0048] In another preferred embodiment, R1 is composed of 0-3 R a1 Independently replaced

[0049] In another preferred embodiment, R1 is composed of 0-3 R a1 Independently replaced

[0050] In another preferred embodiment, R1 is composed of 0-3 R a1 Independently replaced

[0051] In another preferred embodiment, R1 is composed of 0-3 R a1 Independently replaced

[0052] In another preferred embodiment, each R a1 Independently selected from the group consisting of halogen, =O, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, -LC 3-9 Cycloalkyl, -L-(saturated or partially saturated 3-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S), -L-(5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S), -OL-(3-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S), -OR b2 、-N(R b2 )2、-LN(R b2 )2, -C(=O)R b2 、-NR b2 C(=O)R b2 、-NR b2 S(=O)2R b2 , wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl are optionally substituted by a substituent selected from the group consisting of: =O, halogen, -OH, -NH2, -NHC 1-3 Alkyl, -N(C 1-3 Alkyl)2, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, -OC 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S1-6 Heteroalkyl, -OC 1-6 Halogenated alkyl, C 1-6 Haloalkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Haloheteroalkyl, -C(=O)Me, -C(=O)NHMe, -NHC(=O)Me;

[0053] Each L is independently a bond or C 1-6 alkylene;

[0054] Each R b2 Independently selected from the group consisting of H, C 1-6 Alkyl, C 1-6 Haloalkyl, C substituted with 0-1 =O and containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 3-9 Cycloalkyl, 3-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O or S, optionally substituted by =O or -CH3.

[0055] In another preferred embodiment, R a1 The cycloalkyl group has a structure selected from the group consisting of:

[0056] R a1 The heterocyclic group has a structure selected from the following group:

[0057] R a1 The heteroaryl group has a structure selected from the group consisting of:

[0058] In another preferred embodiment, R b2 The heteroalkyl group has a structure selected from the group consisting of:

[0059] R b2 The cycloalkyl group has the following structure:

[0060] R b2 The heterocyclic group has a structure selected from the following group:

[0061] In another preferred embodiment, R is selected from the following group: H, -NH2, C 1-3 Alkyl, -OC 1-3 alkyl;

[0062] R2 is selected from the following group: H, C 1-6 Alkyl, -OR a2 ; or R2 together with the C to which it is connected forms C3-6 Cycloalkyl or 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S; R a2 As defined in claim 1;

[0063] R3 is selected from the group consisting of H, halogen, C 1-6 Alkyl; or, two R3 and the atoms to which they are attached or R3 and the group attached to the nitrogen heterocycle to which they are attached together form a 3-10 membered carbocyclic or heterocyclic ring;

[0064] R4 is selected from the group consisting of halogen, -CN, C 1-3 Alkyl, C 2-6 Alkynyl, C 3-5 Cycloalkyl, 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S, -OR a4 、-C(=O)N(R a4 )2、-S(=O)2N(R a4 )2; R a4 As defined in claim 1;

[0065] R5 is selected from the group consisting of H, halogen, -CN, C 1-3 alkyl.

[0066] In another preferred embodiment, R is -NH2.

[0067] In another preferred embodiment, R2 is C 1-6 alkyl.

[0068] In another preferred embodiment, R3 is selected from the following group: F, -CH3.

[0069] In another preferred embodiment, R4 is selected from the following group: -CH3, -CH2CH3, -C(=O)NH2.

[0070] In another preferred embodiment, R5 is selected from the following group: H, -CH3, F.

[0071] In another preferred embodiment, x1 is selected from the following group: C(R a6 ) m 、N(R a6 ) m , preferably CH.

[0072] In another preferred embodiment, x2 is selected from the following group: C(R a6 ) m 、N(R a6 ) m , preferably CH.

[0073] In another preferred embodiment, x3 is selected from the following group: C(R a6 ) m 、N(Ra6 ) m , preferably CH.

[0074] In another preferred embodiment, the compound is selected from the following group:

[0075] The second aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds according to the first aspect of the present invention and a pharmaceutically acceptable carrier.

[0076] The third aspect of the present invention provides a use of the compound described in the first aspect of the present invention for preparing a medicament for regulating PRMT5 activity or treating PRMT5-related diseases.

[0077] In another preferred embodiment, the PRMT5-related disease is cancer or tumor.

[0078] In another preferred embodiment, the cancer or tumor is selected from the following groups: prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, testicular cancer, etc. More specifically, the cancers that can be treated by the compounds and methods of the present invention include but are not limited to tumor types such as astrocytic carcinoma, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, lung cancer, oral cancer, ovarian cancer, prostate cancer and thyroid cancer and sarcoma. More specifically, these compounds can be used to treat: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, cartilage hamartoma, mesothelioma; Gastrointestinal diseases: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vasodilatory bowel disease) Genitourinary system: kidney (adenocarcinoma, Wilms' tumor, lymphoma, leukemia), bladder and urethra squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma), liver cancer (hepatocellular carcinoma), bile duct cancer, hepatoblastoma, Hemangiosarcoma, hepatocellular adenoma, hemangioma; biliary tract: gallbladder cancer, ampullary cancer, bile duct cancer; bone: bone sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, giant cell tumor of bone chordoma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumor; nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningeal sarcomas, gliomas), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germinal cell tumors (pineal tumors), Glioblastoma multiforme, oligodendroglioma, neurilemoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma); Gynecology: uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulation sheath cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonic rhabdomyosarcoma), fallopian tube (carcinoma);Hematology: Blood (myeloid leukemias (acute and chronic), acute lymphocytic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; Adrenal gland: neuroblastoma. In some cases, the tumor is diffuse large B-cell lymphoma (DLBCL).

[0079] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. DETAILED DESCRIPTION

[0080] After extensive and in-depth research, the inventors unexpectedly developed a bicyclic compound with excellent PRMT5 inhibitory activity and a method for its preparation. Specifically, through structural optimization, the inventors obtained a class of compounds with excellent selective PRMT5 inhibitory activity. Based on this, the inventors completed the present invention.

[0081] the term

[0082] In the present invention, unless otherwise specified, the terms used have the general meanings commonly known to those skilled in the art.

[0083] In the present invention, the term "halogen" refers to F, Cl, Br or I.

[0084] In the present invention, "C 1-6 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, or the like. The term "C 1-3 "Alkyl" has a similar meaning.

[0085] In the present invention, the term "C 2-6 The term "alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including but not limited to ethenyl, propenyl, butenyl, isobutenyl, pentenyl and hexenyl.

[0086] In the present invention, the term "C 2-6 The term "alkynyl" refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms and containing one triple bond, including but not limited to ethynyl, propynyl, butynyl, isobutynyl, pentynyl and hexynyl.

[0087] In the present invention, the term "halo" means substituted with halogen.

[0088] In the present invention, the term "fluoro" refers to substitution with F.

[0089] In the present invention, the term "C 3-6 "Cycloalkyl" refers to a cyclic alkyl group having 3 to 6 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. The term "C 3-5 Cycloalkyl", "C 3-8 Cycloalkyl", "C 5-12 Cycloalkyl", "C 3-9 "Cycloalkyl" has a similar meaning.

[0090] In the present invention, the term "aromatic ring" or "aryl group" has the same meaning, preferably "C 6-10 Aryl". The term "C 6-10 "Aryl" refers to an aromatic ring group with 6 to 10 carbon atoms and no heteroatoms in the ring, such as phenyl, naphthyl, etc. The term "C 5-8 Aryl", "C 8-12 "Aryl" has a similar meaning.

[0091] In the present invention, the term "heterocyclyl" or "heterocycloalkyl" refers to a 3-12 membered heterocyclic group containing 1-4 heteroatoms selected from N, O, and S, including (but not limited to) the following groups:

[0092] In the present invention, the terms "aromatic heterocycle" or "heteroaryl" have the same meaning and refer to heteroaromatic groups containing one to multiple heteroatoms. For example, "C3-C10 heteroaryl" refers to an aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen and 3 to 10 carbon atoms. Non-limiting examples include: furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is the heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.

[0093] In the present invention, the term "C 1-6 "Alkoxy" refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy. The term "C 1-3 "Alkoxy" has a similar meaning.

[0094] In the present invention, the term "C 1-6"Heteroalkyl" refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms containing a heteroatom selected from N, O or S, including but not limited to methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, -CH2OH, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2OCH3, -CH2CH2NHCH3, -CH2CH2N(CH3)2, etc.

[0095] In the present invention, the term "substituted" refers to the replacement of one or more hydrogen atoms on a specific group with a specific substituent. The specific substituent is the substituent described above or the substituent appearing in the examples. Unless otherwise specified, a substituted group may have a substituent selected from the specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically feasible. The substituents include, but are not limited to, halogen, hydroxyl, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amino, C1-C6 alkoxy, C1-C10 sulfonyl, and the like.

[0096] In the present invention, the term 1 to 6 refers to 1, 2, 3, 4, 5 or 6. Other similar terms have similar meanings.

[0097] It should be understood that when a group is present at multiple different positions in a compound, the definition at each position is independent of each other and may be the same or different. That is, the term "selected from the group:" and the term "each independently selected from the group:" have the same meaning.

[0098] Compound

[0099] The present invention provides a compound, which is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof,

[0100] wherein R1, R2, R3, R4, R5, x1, x2, x3, x4, R, and n are as defined above.

[0101] In another preferred embodiment, in the compound, any one of R1, R2, R3, R4, R5, x1, x2, x3, x4, R, and n is independently the corresponding specific group in the specific compound.

[0102] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention formed with an acid or base that is suitable for pharmaceutical use. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts are salts formed with a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid.

[0103] Another preferred salt is a salt of the compound of the present invention formed with a base, such as an alkali metal salt (e.g., sodium salt or potassium salt), an alkaline earth metal salt (e.g., magnesium salt or calcium salt), an ammonium salt (e.g., lower alkanolammonium salt and other pharmaceutically acceptable amine salts), for example, methylamine salt, ethylamine salt, propylamine salt, dimethylamine salt, trimethylamine salt, diethylamine salt, triethylamine salt, tert-butylamine salt, ethylenediamine salt, hydroxyethylamine salt, dihydroxyethylamine salt, trihydroxyethylamine salt, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0104] The term "solvate" refers to a complex in which the compound of the present invention is coordinated with solvent molecules to form a specific ratio.

[0105] In addition, the compounds of the present invention also include prodrugs of the compounds represented by formula (I). The term "prodrug" includes compounds that may be biologically active or inactive, and that, when administered by appropriate methods, undergo metabolic or chemical reactions in the human body to transform into a compound of formula (I), or a salt or solution composed of a compound of formula (I). Such prodrugs include (but are not limited to) carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amino, carbamate, azo, phosphoramide, glucoside, ether, acetal, and other forms of the compounds.

[0106] It should be understood that the specific preparation method of the compound of formula (I) of the present invention does not constitute any limitation to the present invention. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily performed by those skilled in the art to which the present invention belongs.

[0107] Typically, the compounds of the present invention can be prepared by the process described in the examples, wherein the raw materials and reagents used can be purchased from commercial sources unless otherwise specified.

[0108] Pharmaceutical compositions and methods of administration

[0109] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one or more of the compounds and a pharmaceutically acceptable carrier.

[0110] Since the compounds of the present invention have excellent anti-tumor activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate tumor-related diseases.

[0111] The pharmaceutical composition of the present invention comprises a safe and effective amount of a compound of the present invention or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 10-1000 mg of the compound of the present invention per dose. Preferably, "one dose" is one capsule or tablet.

[0112] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0113] The pharmaceutical composition is in the form of injection, capsule, tablet, pill, powder or granule.

[0114] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration routes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0115] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0116] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.

[0117] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.

[0118] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0119] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0120] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0121] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0122] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as anti-tumor drugs).

[0123] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0124] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage will also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.

[0125] Compared with the prior art, the present invention has the following main advantages:

[0126] 1) The compound has excellent PRMT5 selective inhibitory activity against MTAP deficiency.

[0127] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, were generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0128] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0129] Example Synthesis Route

[0130] Unless otherwise indicated, the absolute stereochemistry of all chiral atoms is defined as follows. Compounds labeled (or) or (rel) are single enantiomers with arbitrarily specified absolute stereochemistry (e.g., based on chiral SFC elution described in the Examples section). Compounds labeled (&) or (rac) are mixtures of enantiomers with relative stereochemistry as indicated in the text. Compounds labeled with (abs) are single enantiomers with absolute stereochemistry as indicated in the text.

[0131] Synthesis of intermediates

[0132] Synthesis of intermediate int1:

[0133] 1. Synthesis of int1-2

[0134] Dissolve int1-1 (5 g, 28.25 mmol) in 100 mL of anhydrous tetrahydrofuran. Under nitrogen, cool the reaction mixture to -78°C. Then, slowly add sodium bis(trimethylsilyl)amide (21.19 mL, 56.3 mmol, 2M in THF) dropwise. Maintain the temperature and stir for 0.5 h. Then, slowly add 500 mL of a tetrahydrofuran solution of N-bromosuccinimide (6.54 g, 36.73 mmol) dropwise. Maintain the temperature and stir for 2 h. After the reaction is complete, warm the reaction system to room temperature and quench the reaction with 2 M dilute hydrochloric acid. Extract three times with ethyl acetate, wash with saturated brine, combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify to obtain 3.94 g of product. Ms[M+H] + 255.9 1 H NMR (400MHz, DMSO-d6) δ5.92 (d, J = 16.3Hz, 1H), 4.32-4.14 (m, 4H), 1.31 (m, 6H).

[0135] 2. Synthesis of int1-4

[0136] Sodium hydride (927 mg, 23.18 mmol) was dissolved in 40 mL of anhydrous tetrahydrofuran. Under nitrogen protection, an ice-water bath was used to slowly add a tetrahydrofuran solution (70 mL) of int1-2 (3.94 g, 15.45 mmol) dropwise. The mixture was stirred at this temperature for 0.5 h. Then, a tetrahydrofuran solution (50 mL) of int1-3 (2.77 g, 23.18 mmol) was slowly added dropwise. The temperature was slowly raised to 25°C and the reaction was continued for 0.5 h. After the reaction of the raw materials was complete, the reaction system was warmed to room temperature. The reaction solution was diluted with saturated brine and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 2.8 g of the product. Ms[M+H] +280.9 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),8.38(d,J=2.0Hz,1H),8.02(dd,J=8.8,2.0Hz,1H),7.54(d,J=8.8Hz,1H),7.12(s,2H),3.88(s,3H).

[0137] 3. Synthesis of int1-5

[0138] Dissolve int1-4 (2.8 g, 10 mmol) in 280 mL of dioxane, then sequentially add methylboric acid (11.97 g, 20 mmol), sodium carbonate (3.18 g, 30 mmol), and Pd(dppf)Cl2 (732 mg, 1 mmol). Under nitrogen protection, the mixture was replaced three times. The reaction solution was slowly heated to 100°C and reacted for 3 hours. After the raw materials reacted completely, the reaction system was cooled to room temperature, concentrated under reduced pressure, and purified to obtain 1.4 g of product. Ms[M+H] + 217.0. 1 H NMR (400MHz, DMSO-d6) δ8.21(d,J=2.0Hz,1H),7.86(dd,J=8.7,2.1Hz,1H),7.82(s,1H),7.42(d,J=8.7Hz,1H),6.68(s,2H),3.80(s,3H),2.16(s,3H).

[0139] 4. Synthesis of int1

[0140] Int1-5 (1.4 g, 6.48 mmol) was dissolved in 100 mL of a mixed solvent consisting of tetrahydrofuran, methanol, and water (2:1:1). Lithium hydroxide (1.09 g, 25.92 mmol) was added and stirred at 25°C for 12 h. After the reaction was complete, the pH was adjusted to 7 with 2 M dilute hydrochloric acid. A large amount of white solid precipitated, which was filtered and the filter cake was vacuum dried to obtain 0.7 g of product. Ms[M+H] + 202.9 1 H NMR (400MHz, DMSO-d6) δ8.24(d,J=2.0Hz,1H),7.91(dd,J=8.7,2.0Hz,1H),7.86(s,1H),7.46(d,J=8.7Hz,1H),6.66(s,2H),2.22(d,J=1.1Hz,3H).

[0141] Synthesis of intermediate int2:

[0142] Oxalyl chloride (9.4 g, 73.8 mmol) was dissolved in 600 mL of dichloromethane. Under nitrogen protection, the reaction solution was cooled to -78 ° C, and then dimethyl sulfoxide (16.8 g, 199.45 mmol) was slowly added dropwise. After the temperature was maintained at -78 ° C and stirred for 1 h, 100 mL of dichloromethane solution of int2-1 (9.3 g, 39.89 mmol) was slowly added dropwise, and then the temperature was maintained at -78 ° C and stirred for 0.5 h. Triethylamine (20 g, 199.45 mmol) was then added dropwise. After the raw material reaction was complete, the reaction system was warmed to room temperature, the reaction solution was diluted with saturated brine, extracted three times with dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 9.2 g of product.

[0143] 1 H NMR(400MHz,DMSO-d6)δ9.65(d,J=6.4Hz,1H),3.88(d,J=13.6Hz,2H),3.01( s,2H),1.79(dd,J=9.2,4.2Hz,2H),1.76-1.65(m,2H),1.40(d,J=5.2Hz,9H).

[0144] Synthesis of intermediate int3:

[0145] 1. Synthesis of int3-2

[0146] Dissolve int3-1 (3 g, 26.5 mmol) in 75 mL of anhydrous tetrahydrofuran. Under nitrogen, cool the reaction mixture to -78°C and slowly add n-butyl lithium (10.6 mL, 26.5 mmol, 2.5 M in THF) dropwise. Stir for 30 min. Then, maintain the temperature at -78°C and slowly add a solution of di-tert-butyl dicarbonate (8.7 g, 39.8 mmol) in 36 mL of tetrahydrofuran dropwise. Stir for 40 min. Quench the reaction with saturated ammonium chloride solution, extract with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify to yield 3.96 g of product. Ms[M+H] + 236.1 1 H NMR(400MHz,Chloroform-d)δ3.83-3.75(m,1H),3.16-3.06(m,1H),2.57-2.52(m,1H),2.52-2.46( m,1H),2.02-1.93(m,1H),1.92-1.84(m,1H),1.53(s,9H),1.44-1.39(m,1H),1.04(d,J=6.6Hz,3H).

[0147] 2. Synthesis of int3

[0148] Dissolve int3-2 (4 g, 18.77 mmol) in 40 mL of anhydrous tetrahydrofuran. Cool the reaction mixture to -78°C under nitrogen and slowly add lithium bis(trimethylsilyl)amide (28.2 mL, 28.16 mmol, 1 M in THF) dropwise. Stirring is continued for 1.5 h. Then, while maintaining the temperature, slowly add 20 mL of a tetrahydrofuran solution of N-phenylbis(trifluoromethanesulfonimide) (4.2 g, 23.46 mmol) dropwise. Continue the reaction for 2 h. Quench the reaction by dropwise addition of saturated ammonium chloride solution, warm the mixture to room temperature, extract with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify to obtain 4.28 g of the product. Ms[M+H] + 346.1 1 H NMR(400MHz,Chloroform-d)δ5.25(t,J=3.8Hz,1H),3.87(dd,J=12.8,3.3Hz,1H),3.00(dd,J =12.7,9.1Hz,1H),2.44-2.34(m,1H),1.98-1.78(m,2H),1.49(s,9H),0.99(d,J=6.6Hz,3H).

[0149] Synthesis of intermediate int4:

[0150] 1. Synthesis of int4-2

[0151] Int4-1 (3 g, 15.31 mmol) was dissolved in 50 mL of N,N-dimethylformamide, and N,N-dimethylformamide dimethyl acetal was added. Under nitrogen, the reaction mixture was heated to 90°C for 2 h. After the reaction of the starting materials was complete, the reaction system was cooled to room temperature, concentrated under reduced pressure, and purified to obtain 3.69 g of the product. Ms[M+H] + 252.0 1 H NMR (400MHz, DMSO-d6) δ8.85(s,1H),8.22(s,1H),8.14(d,J=13.0Hz,1H),5.85(d,J=13.0Hz,1H),3.88(s,3H),3.25-2.80(m,6H).

[0152] 2. Synthesis of int4-3

[0153] Int4-2 (3.69 g, 14.7 mmol) was dissolved in a mixed solvent consisting of 50 mL of tetrahydrofuran and 50 mL of water. The reaction mixture was stirred at room temperature overnight. After the reaction was complete, saturated sodium bicarbonate solution was added to adjust the pH to 8 under ice-water cooling. The reaction mixture was filtered, the filter cake was washed with ethyl acetate, and the filtrate was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 2.67 g of crude product. 1 H NMR (400MHz, DMSO-d6) δ10.36(s,1H),9.47(s,1H),8.33(s,1H),3.97(s,3H).

[0154] 3. Synthesis of int4-4

[0155] Int4-3 (2.67 g, 12.8 mmol) was dissolved in 140 mL of acetic acid, and iron powder (7.12 g, 127 mmol) was added. Under nitrogen, the reaction mixture was heated to 50°C for 30 min. After the reaction was complete, the reaction mixture was cooled to room temperature and filtered. The filter cake was washed with ethyl acetate and the filtrate was evaporated to dryness under reduced pressure. The residue was then dissolved in ethyl acetate and cooled in an ice-water bath. Saturated sodium bicarbonate solution was added to adjust the pH to 8. The mixture was extracted with ethyl acetate. The organic phases were combined, concentrated under reduced pressure, and purified to yield 1.3 g of product. Ms[M+H] + 181.0 1 H NMR (400MHz, DMSO-d6) δ10.01(s,1H),8.31(s,1H),8.26(s,1H),7.81(s,2H),3.82(s,3H).

[0156] 4. Synthesis of int4-6

[0157] Under ice-water cooling, sodium hydride (433 mg, 10.83 mmol) was dissolved in 40 mL of N,N-dimethylformamide. Under nitrogen protection, a solution of int4-5 (4.7 g, 18.41 mmol) in tetrahydrofuran (40 mL) was slowly added dropwise to the reaction system. After stirring for 30 minutes, int4-4 (1.3 g, 7.22 mmol) was slowly added dropwise and stirring continued for 2 hours. After the raw materials reacted completely, water was added dropwise under ice-water cooling to quench the reaction. The reaction system was warmed to room temperature and extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 1.4 g of product. Ms[M+H] + 281.9 1 H NMR (400MHz, DMSO-d6) δ8.87 (d, J = 0.8Hz, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 7.42 (s, 2H), 3.89 (s, 3H).

[0158] 5. Synthesis of int4-7

[0159] Int4-6 (1.2 g, 4.27 mmol), methylboronic acid (512 mg, 8.54 mmol), potassium carbonate (1.7 g, 12.81 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (307 mg, 0.42 mmol) were dissolved in 60 mL of ethylene glycol dimethyl ether. Under nitrogen, the reaction mixture was heated to 85°C for 3 hours. After the reaction was complete, the reaction system was cooled to room temperature and filtered. The filter cake was washed with ethyl acetate, and the filtrate was concentrated under reduced pressure and purified to yield 900 mg of the product. Ms[M+H] + 218 1 H NMR (400MHz, DMSO-d6) δ8.81(s,1H),8.31(s,1H),7.96(s,1H),7.03(s,2H),3.87(s,3H),2.26(s,3H).

[0160] 6. Synthesis of int4

[0161] Dissolve int4-7 (900 mg, 4.12 mmol) in a mixed solvent consisting of 20 mL of tetrahydrofuran, 10 mL of methanol, and 10 mL of water. Add lithium hydroxide monohydrate (260 mg, 6.18 mmol) and stir at room temperature for 3 h. After the reaction is complete, concentrate under reduced pressure to obtain 1.0 g of crude product. Ms[M+H] + 204 1 H NMR(400MHz,D2O)δ8.60(s,1H),7.97(s,1H),7.64(s,1H),2.12(s,3H).

[0162] Synthesis of intermediate int5

[0163] 1. Synthesis of int5-2

[0164] Int5-1 (23 g, 106.83 mmol) was dissolved in 460 mL of dichloromethane. Under nitrogen, the reaction solution was cooled to 0°C and triethylamine (16.18 g, 160.25 mmol) was added, followed by the slow dropwise addition of methylsulfonyl chloride (14.68 g, 128.20 mmol). The reaction solution was allowed to warm to room temperature and stirred for 12 hours. After the reaction of the starting materials was complete, water was added to quench the reaction, and the mixture was allowed to stand for the dichloromethane phase. The aqueous phase was extracted three times with dichloromethane, separated, and the combined dichloromethane phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 30 g of the product. Ms[M+H-56] + 238.0.1 H NMR (400MHz, Chloroform-d) δ4.16-4.04 (m, 2H), 4.01-3.88 (m, 1H), 3.81 (d, J = 13.2Hz, 1H), 3.03 (s, 3H), 2.93-2. 96(m,1H),2.80(s,1H),2.01-1.90(m,1H),1.88-1.77(m,1H),1.68-1.71(m,2H),1.46(s,9H),1.37-1.23(m,1H).

[0165] 2. Synthesis of int5-3

[0166] Dissolve int5-2 (5 g, 17.06 mmol) in 100 mL of anhydrous tetrahydrofuran. Under nitrogen, cool the reaction mixture to -30°C and slowly add lithium triethylborohydride (107 mL, 106.63 mmol, 1 M in THF) dropwise. After the reaction is complete, slowly warm the mixture to room temperature and stir for 12 hours. After the reaction is complete, water is added dropwise to quench the reaction. The mixture is then extracted three times with ethyl acetate. The combined organic phases are dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 1.6 g of product. Ms[M+H-56] + 144.1. 1 H NMR(400MHz,Chloroform-d)δ3.92(dd,J=17.2,10.2Hz,2H),2.69-2.73(m,1H),2.25(d,J=20.3Hz,1H),1.8 1-1.68(m,1H),1.67-1.50(m,2H),1.46(s,9H),1.31-1.18(m,1H),1.11-0.92(m,1H),0.87(d,J=6.7Hz,3H).

[0167] 3. Synthesis of int5-4

[0168] Int5-3 (1.6 g, 8.03 mmol) and sodium periodate (5.84 g, 27.30 mmol) were dissolved in 30 mL of ethyl acetate and 30 mL of water. Ruthenium(IV) oxide hydrate (122 mg, 0.81 mmol) was added and stirred at room temperature for 12 hours under nitrogen. After the reaction was complete, the reaction was quenched with saturated sodium sulfite solution. The mixture was then extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 790 mg of the product. Ms[M+H-56] + 158.1. 1H NMR(400MHz,Chloroform-d)δ3.79(dd,J=12.7,4.8Hz,1H),3.12(dd,J=12.6,10.3Hz,1H),2.67-2.39 (m,2H),1.95-1.98(m,1H),1.94-1.78(m,1H),1.53(s,9H),1.47-1.38(m,1H),1.04(d,J=6.6Hz,3H).

[0169] 4. Synthesis of int5

[0170] Dissolve int5-4 (0.79 g, 3.71 mmol) in 50 mL of anhydrous tetrahydrofuran. Under nitrogen, cool to -78°C and slowly add hexamethyldisilazane lithium salt (5.57 mL, 5.57 mmol, 1 M in THF) dropwise. Stir for 0.5 h. Then, maintain the temperature at -78°C and slowly add N-phenylbis(trifluoromethanesulfonyl)imide (1.66 g, 4.64 mmol) in 20 mL of anhydrous tetrahydrofuran dropwise. Maintain the temperature for 0.5 h, then warm to room temperature and stir for 3 h. After the reaction is complete, water is added dropwise to quench the reaction. Extract three times with ethyl acetate, combine the organic phases, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify to yield 1.2 g of compound 5-4. + 290.0. 1 H NMR (400MHz, Chloroform-d) δ5.25 (t, J=3.8Hz, 1H), 3.87 (dd, J=12.8, 3.3Hz, 1H), 3.00 (dd, J=12.7, 9. 1Hz,1H),2.44-2.34(m,1H),1.98-1.85(m,1H),1.85-1.78(m,1H),1.49(s,9H),0.99(d,J=6.6Hz,3H).

[0171] Synthesis of intermediate int6

[0172] 1. Synthesis of int6-2

[0173] Int6-1 (500 mg, 4.42 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran. Under nitrogen, the reaction solution was cooled to -78°C and n-butyl lithium (1.8 mL, 4.42 mmol, 2.5 M in THF) was slowly added dropwise. Stirring was continued for 30 min. Then, a solution of di-tert-butyl dicarbonate (1.44 g, 6.63 mmol) dissolved in 80 mL of tetrahydrofuran was slowly added dropwise, maintaining the temperature at -78°C. Stirring was continued for 40 min. Saturated ammonium chloride solution was added dropwise, maintaining the temperature at -78°C, to quench the reaction. The mixture was then stirred and warmed to room temperature. The reaction solution was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 500 mg of the product. Ms[M+H] + 213.1. 1 H NMR (400MHz, Chloroform-d) δ4.25-4.34(m,1H),2.57-2.34(m,2H),2.01-1.82(m,2H),1.82-1.64(m,2H),1.53(s,9H),1.28(d,J=6.6Hz,3H).

[0174] 2. Synthesis of C5-3

[0175] Int6-2 (500 mg, 2.35 mmol) was dissolved in 40 mL of anhydrous tetrahydrofuran. Under nitrogen, the reaction solution was cooled to -78°C and lithium bis(trimethylsilyl)amide (3.45 mL, 3.45 mmol, 1 M in THF) was slowly added dropwise. Stirring was continued for 1.5 h. Then, 20 mL of a tetrahydrofuran solution of N-phenylbis(trifluoromethanesulfonimide) (1.05 g, 2.88 mmol) was slowly added dropwise while maintaining the temperature. The reaction was continued for 2 h. After the reaction, saturated ammonium chloride solution was added dropwise while maintaining the temperature at -78°C to quench the reaction. The mixture was then stirred and warmed to room temperature. The mixture was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 800 mg of the product. Ms[M+H] + 346.1

[0176] Synthesis of intermediate int7

[0177] 1. Synthesis of int7-2

[0178] (S)-(-)-1-Amino-2-propanol (1.00 g, 13.30 mmol) and triethylamine (3.7 mL, 26.60 mmol) were dissolved in 20 mL of anhydrous dichloromethane. Triphenylmethane (3.90 g, 14.0 mmol) was added under nitrogen and cooled in an ice-water bath. The mixture was then warmed to room temperature and stirred overnight. After completion of the reaction, the reaction solution was diluted with water and extracted three times with dichloromethane. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 3.86 g of product. 1 H NMR (400MHz, Chloroform-d) δ7.51-7.40(m,6H),7.34-7.24(m,6H),7.24-7.14(m,2H),3.80(m,1H),2.23-2.11(m,2H),1.11(d,J=6.2Hz,3H).

[0179] 2. Synthesis of int7-3

[0180] Under ice-water cooling, 60% sodium hydride (388 mg, 9.70 mmol) was added to 5 mL of anhydrous N,N-dimethylformamide. Under nitrogen protection, int7-2 solution (1.54 g, 4.85 mmol, in 15 mL of DMF) was added dropwise, and the mixture was warmed to room temperature and stirred for 1 hour. Then, under ice-water cooling, tributyl (iodomethyl) stannane (2.30 g, 5.34 mmol) was added dropwise, and the mixture was warmed to room temperature and stirred for 4 hours. After the reaction was completed, saturated potassium fluoride solution was added to quench the reaction, and the mixture was extracted with ethyl acetate three times. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 1.96 g of product. 1 H NMR(400MHz,Chloroform-d)δ7.60-7.40(m,6H),7.33-7.21(m,6H),7.19-7.07(m,3H), 3.78-3.64(m,1H),3.45(d,J=9.9Hz,1H),3.36(dq,J=6.8,3.4Hz,1H),2.23(dd,J=11.8,3.5Hz,1H),2.09(dd,J =11.8,7.2Hz,1H),1.60-1.39(m,6H),1.32-1.26(m,6H),1.10(d,J=6.2Hz,3H),0.90-0.82(m,15H).3, synthesis of int7

[0181] Int7-3 (1.96 g, 3.16 mmol) was dissolved in a 14 mL / 4 mL / 2 mL mixture of dichloromethane / 2,2,2-trifluoroethanol / acetic acid. The reaction mixture was heated to 50°C and stirred for 18 hours. After completion of the reaction, the mixture was cooled in an ice bath and adjusted to a weak alkaline state by adding saturated sodium bicarbonate solution. The mixture was then extracted three times with dichloromethane. The combined dichloromethane phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to yield 834 mg of the product. Ms[M+H] + 380.1. 1 H NMR(400MHz,Chloroform-d)δ3.83(d,J=9.8Hz,1H),3.55(d,J=9.8Hz,1H),3.32-3.12(m,1H),2.78(dd,J=13.1,3.6Hz,1H ),2.62(dd,J=13.0,7.4Hz,1H),1.61-1.39(m,7H),1.38-1.24(m,7H),1.10(d,J=6.2Hz,3H),0.90(td,J=7.8,3.6Hz,15H).

[0182] Synthesis of intermediate int8

[0183] 1. Synthesis of int8-2

[0184] (R)-(-)-2-Amino-1-propanol (500 mg, 6.67 mmol) was dissolved in 30 mL of anhydrous dichloromethane. Triethylamine (1.87 mL, 13.34 mmol) and triphenylmethane (1.95 g, 6.70 mmol) were added sequentially under ice-water cooling, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, water was added to quench the reaction, and the mixture was extracted three times with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 1.94 g of the product. 1 H NMR(400MHz,Chloroform-d)δ7.61-7.48(m,6H),7.29-7.22(m,6H),7.21-7.13(m,3H),3.15(d d,J=10.5,4.2Hz,1H),3.04(dd,J=10.6,4.9Hz,1H),2.79-2.72(m,1H),0.66(d,J=6.5Hz,3H).

[0185] 2. Synthesis of int8-3

[0186] Under ice-water cooling, 60% sodium hydride (367 mg, 9.18 mmol) was added to 12 mL of anhydrous N,N-dimethylformamide. Under nitrogen, 8 mL of a solution of compound int8-2 (1.94 g, 6.12 mmol) in anhydrous N,N-dimethylformamide was added dropwise to the reaction mixture. The mixture was warmed to room temperature and stirred for 1 hour. Tributyl(iodomethyl)stannane (2.9 g, 6.73 mmol) was then added dropwise under ice-water cooling, followed by stirring at room temperature for 2 hours. After completion of the reaction, saturated potassium fluoride solution was added to quench the reaction, and the mixture was extracted three times with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to yield 3.24 g of the product. 1 H NMR(400MHz,Chloroform-d)δ7.60-7.52(m,6H),7.28-7.22(m,6H),7.19-7.12(m,3H),3.46-3.38(m,2H),2.94(dd,J=8.9,4.7Hz,1H),2 .64(dd,J=6.5,4.8Hz,1H),2.44(dd,J=8.9,5.0Hz,1H),1.51-1.40(m,6H),1.28-1.22(m,6H),0.91-0.84(m,15H),0.76(d,J=6.5Hz,3H).

[0187] 3. Synthesis of int8

[0188] Compound int8-3 (3.24 g, 5.22 mmol) was dissolved in a 14 mL / 4 mL / 2 mL mixture of dichloromethane / 2,2,2-trifluoroethanol / acetic acid. The reaction mixture was then heated to 50°C and stirred for 2 h. After the reaction was completed, the mixture was cooled to room temperature and cooled in an ice bath. Saturated sodium bicarbonate solution was added to adjust the mixture to a weak base. The mixture was then extracted three times with dichloromethane. The combined dichloromethane phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to yield 1.41 g of the product. 1 H NMR(400MHz,Chloroform-d)δ3.77-3.68(m,2H),3.31-3.20(m,1H),3.16-3.03(m,2 H),1.62-1.41(m,6H),1.35-1.26(m,6H),1.05(d,J=6.2Hz,3H),0.96-0.82(m,15H).

[0189] Synthesis of intermediate int9

[0190] Int3 (1.5 g, 4.37 mmol), pinacol diboronate (1.29 g, 5.25 mmol), potassium carbonate (900 mg, 6.56 mmol), triphenylphosphine (70 mg, 0.16 mmol), and bis(triphenylphosphine)palladium dichloride (92 mg, 0.13 mmol) were dissolved in 30 mL of dioxane. Under nitrogen, the reaction mixture was heated to 90°C for 7 hours. After the reaction was complete, the reaction system was cooled to room temperature and filtered. The filter cake was washed with ethyl acetate, and the filtrate was concentrated under reduced pressure and purified to yield 1.03 g of product. 1 H NMR (400MHz, DMSO-d6) δ5.00 (s, 1H), 3.61-3.53 (m, 1H), 2.84 (dd, J = 12.4, 9.5Hz, 1H), 2.12-2.01(m,1H),1.82-1.72(m,1H),1.65-1.55(m,1H),1.15(s,12H),0.90(d,3H).

[0191] Synthesis of intermediate int10

[0192] Int10-1 (15 g, 47.61 mmol) was slowly added to 35 mL of trifluoroacetic acid under ice-water cooling and stirred at room temperature for 1.5 h. After the reaction was complete, ice water was added under ice-water cooling until a white solid precipitated. The solid was filtered and the filter cake was washed several times with water. The filter cake was dissolved in 60 mL of dichloromethane, dried over anhydrous sodium sulfate, filtered, and the filtrate was used directly in the next reaction.

[0193] Example 1

[0194] Compounds of the present invention

[0195] The synthetic route and experimental process are as follows:

[0196] 1. Synthesis of C1-2A and C1-2B

[0197] C1-1 (4.16 g, 26.06 mmol) was dissolved in 120 mL of N,N-dimethylformamide, followed by the addition of int2 (6.05 g, 26.06 mmol) and acetic acid (3.08 g, 52.12 mmol). Under nitrogen, the reaction solution was slowly heated to 120°C and stirred for 12 hours. After the reaction of the raw materials was complete, the reaction system was cooled to room temperature and the reaction solution was diluted with saturated brine and extracted three times with methyl tert-butyl ether. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 2.3 g of compound C1-2A and 3.15 g of compound C1-2B.

[0198] C1-2A:Ms[M+H] + 371.0 1 H NMR (400MHz, DMSO-d6) δ8.22(d,J=8.6Hz,1H),8.15(d,J=2.1Hz,1H),7.56(dd,J=8.7,2.1Hz,1H),3 .98(d,J=13.4Hz,2H),3.20(dd,J=23.4,6.1Hz,2H),2.25-2.09(m,4H),1.44(s,9H).C1-2B:Ms[M+H] + 369.0 1 H NMR (400MHz, DMSO-d6) δ8.12(d,J=8.6Hz,1H),8.03(d,J=2.0Hz,1H),7.47(dd,J=8.6,2.1Hz,1H),6.50(s ,1H),3.89(d,J=13.2Hz,2H),3.25-3.01(m,2H),2.07-1.93(m,2H),1.80(d,J=13.4Hz,2H),1.43(s,9H).

[0199] 2. Synthesis of C1-3

[0200] Dissolve C1-2A (2.3 g, 6.21 mmol) in 10 mL of methanol, add 10 mL of 4 M hydrogen chloride-dioxane solution, and stir the reaction mixture for 2 h in an ice-water bath. After the reaction is complete, warm the reaction mixture to room temperature and concentrate under reduced pressure to yield 2 g of product. Ms[M+H] + 271.0

[0201] 3. Synthesis of C1-4

[0202] Dissolve C1-3 (2 g, 7.41 mmol) in 100 mL of methanol, add 37% formaldehyde methanol solution (1.8 g, 22.23 mmol), then sequentially add sodium acetate (668 mg, 8.15 mmol) and acetic acid (1.3 g, 22.23 mmol). Stir the reaction mixture for 1 hour in an ice-water bath under nitrogen protection. Then, add sodium cyanoborohydride (931 mg, 14.82 mmol), and warm the reaction mixture to 30°C for 0.5 hour. After the reaction is complete, cool the reaction mixture to room temperature, adjust the pH to 8 with saturated potassium carbonate solution, and extract three times with dichloromethane. The organic phases are combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 1.35 g of product. Ms[M+H] + 285.0 1H NMR (400MHz, DMSO-d6) δ8.10(d,J=8.6Hz,1H),8.04(d,J=2.0Hz,1H),7.44(dd,J=8. 6,2.1Hz,1H),2.80-2.67(m,2H),2.36-2.24(m,2H),2.22(s,3H),2.18-2.00(m,4H).

[0203] 4. Synthesis of C1-5

[0204] C1-4 (1.35 g, 4.75 mmol) and bis-pinacol boronate (2.17 g, 8.55 mmol) were dissolved in 50 mL of dioxane. X-phos (452.2 mg, 0.95 mmol), potassium acetate (932.33 mg, 9.5 mmol), and Pd2(dba)3 (435 mg, 0.475 mmol) were then added sequentially. Under nitrogen, the reaction mixture was slowly heated to 90°C and stirred for 5 h. After the reaction of the starting materials was complete, the reaction mixture was cooled to room temperature, concentrated under reduced pressure, and purified to yield 1.33 g of the product. Ms[M+H] + 377.2

[0205] 5. Synthesis of C1-6

[0206] C1-5 (1.1 g, 2.92 mmol) and int3 (1.21 g, 3.51 mmol) were dissolved in 50 mL of dioxane, followed by the addition of sodium carbonate (0.93 g, 8.76 mmol) and Pd(dppf)Cl2 (107 mg, 0.146 mmol). Under nitrogen, the reaction mixture was slowly heated to 90°C and stirred for 5 hours. After the starting materials reacted completely, the reaction mixture was cooled to room temperature, diluted with saturated brine, and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 1.28 g of product. Ms[M+H] + 446.2 1 H NMR (400MHz, DMSO-d6) δ8.06(d,J=8.3Hz,1H),7.86(d,J=1.7Hz,1H),7.37(dd,J=8.4,1.7Hz,1H),5.47(s,1H),4.10(s,1H),3.92-3.94(m,2H) ,3.18(s,3H),3.06(dd,J=2.3,8.8Hz,1H),2.74(d,J=9.0Hz,2H),2.46- 2.27(m,3H),2.25(s,3H),2.13(t,2H),1.96-1.80(m,2H),1.07(s,9H).

[0207] 6. Synthesis of C1-7

[0208] Dissolve C1-6 (1.2 g, 4.5 mmol) in 10 mL of trifluoroacetic acid and react at 30°C for 1 h. After the reaction is complete, cool the reaction system to room temperature, concentrate under reduced pressure, and adjust the pH to 8 by adding saturated sodium bicarbonate. Extract three times with dichloromethane. The combined organic phases are dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield 844 mg of crude product. Ms[M+H] + 346.2

[0209] 7. Synthesis of C1-8

[0210] Dissolve C1-7 (844 mg, 2.45 mmol) in 10 mL of methanol, add sodium borohydride (186 mg, 4.89 mmol), and react at 30°C for 1 h. After the reaction is complete, cool the reaction system to room temperature and concentrate under reduced pressure. The reaction solution is diluted with saturated brine and extracted three times with dichloromethane. The organic phases are combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 1.0 g of crude product. Ms[M+H] + 348.1 1 H NMR (400MHz, DMSO-d6) δ8.04(d,J=8.2Hz,1H),7.99(s,1H),7.54-7.47(m,1H),3.64(d,J=10.9Hz,1H),3.04(d,J=11.2Hz,1H),2.75(d,J=9.0Hz,2H ),2.33(d,J=12.8Hz,2H),2.26(s,3H),2.13(d,J=11.8Hz,2H),1.77(d,J =12.8Hz,3H),1.56(s,1H),1.39(d,J=12.1Hz,2H),0.85(d,J=6.6Hz,3H).

[0211] 8. Synthesis of C1-9

[0212] C1-8 (100 mg, 0.5 mmol) was dissolved in 5 mL of N,N-dimethylformamide, and triethylamine (101 mg, 1 mmol) and compound 8 (260 mg, 0.75 mmol) were added sequentially. Finally, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (390 mg, 0.75 mmol) was added, and the mixture was stirred at 30°C for 1 h. After the reaction of the starting materials was complete, the reaction system was cooled to room temperature and concentrated under reduced pressure. The reaction solution was diluted with saturated brine and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 220 mg of the product after purification.

[0213] 9. Synthesis of C1 and C2

[0214] Compound C1-9 was separated and prepared by chiral high performance liquid chromatography to obtain compounds C1 and C2. C1: Ms[M+H] + 532.3 1 H NMR (400MHz, DMSO-d6) δ8.18(d,J=8.5Hz,1H),7.98(s,1H),7.81(s,1H),7.72(d,J=1.5Hz,1H) ,7.48(dd,J=5.6,1.4Hz,3H),6.47(s,2H),4.05(s,1H),3.76(s,1H),3.15(d,J=13.3Hz,1H),2. 82-2.64(m,2H),2.47-2.27(m,4H),2.25(s,3H),2.23(s,3H),2.15(t,2H),2.04-1.91(m,1H), 1.82(s,1H),1.68(d,J=13.3Hz,1H)1.36(d,J=13.2Hz,1H),1.23(s,2H),0.99(d,J=6.9Hz,3H).

[0215] C2: Ms[M+H] + 532.3 1 H NMR (400MHz, DMSO-d6) δ8.18(d,J=8.5Hz,1H),7.98(s,1H),7.81(s,1H),7.71(d,J=1.5Hz ,1H),7.48(dd,J=5.6,1.4Hz,3H),6.47(s,2H),3.76(s,1H),3.15(d,J=13.3Hz,1H),2.77( d,J=10.2Hz,2H),2.38-2.27(m,4H),2.25(s,3H),2.21(s,3H),2.14(t,2H),2.07-1.92(m, 1H),1.82(s,1H),1.70(t,1H),1.36(d,J=13.2Hz,1H),1.23(s,2H),0.99(d,J=6.9Hz,3H).

[0216] The separation conditions are as follows:

[0217] Instrument: Agilent 1260 II

[0218] Column: Phenomenex 5μm Amylose-1 (250 x 30mm)

[0219] Mobile phase: n-hexane:ethanol = 75:25

[0220] Flow rate: 15 mL / min, detection wavelength: 254 nm

[0221] Column temperature: 25°C, solvent: ethanol

[0222] Injection concentration: 20 mg / mL, injection volume: 200 μL

[0223] Peak time: 22.556 min (C1), 26.334 min (C2)

[0224] The above synthesis method was used to synthesize the compounds in the following table:

[0225] Example 2

[0226] Compounds of the present invention

[0227] The synthetic route and experimental process are as follows:

[0228] 1. Synthesis of C7-3

[0229] Dissolve C7-1 (10 g, 35.33 mmol) and C7-2 (7.38 g, 35.33 mmol) in 120 mL of tetrahydrofuran. Add cuprous iodide (1.34 g, 7.07 mmol), tetrakistriphenylphosphine palladium (4 g, 3.5 mmol), and triethylamine (15 mL, 106 mmol) in that order. Stir at room temperature under nitrogen for 20 h. After the reaction is complete, filter the mixture, concentrate the filtrate under reduced pressure, and then purify it to obtain 4.3 g of the product. Ms[M+H] + 365.1. 1 H NMR (400MHz, DMSO-d6) δ8.65(dd,J=2.4,0.8Hz,1H),8.04(dd,J=8.4,2.5Hz,1H),7.45(dd,J=8.4,0.8Hz,1H) ,3.70-3.58(m,2H),3.18-3.06(m,2H),2.94-2.85(m,1H),1.89-1.79(m,2H),1.57-1.48(m,2H),1.40(s,9H).

[0230] 2. Synthesis of C7-4

[0231] To a freshly prepared solution of int10 (4 eq) in dichloromethane (60 mL) was slowly added dropwise a solution of C7-3 (3.1 g, 8.5 mmol) dissolved in 25 mL of dichloromethane under ice-water cooling. Stirring was continued for 1.5 h. Solids precipitated upon addition of petroleum ether. Filter the filter cake and dry under reduced pressure to yield 1.5 g of product.

[0232] 3. Synthesis of C7-5

[0233] Under ice-water cooling, C7-4 (1.5 g, 3.9 mmol) was dissolved in 15 mL of N,N-dimethylformamide. Potassium carbonate (1 g, 7.9 mmol) was slowly added, and the reaction was stirred for 1 h. After completion of the reaction, water was added to quench the reaction under ice-water cooling. The reaction was extracted three times with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 1.23 g of product. Ms[M+H] + 324.0. 1 H NMR (400MHz, DMSO-d6) δ8.98-8.93(m,1H),7.58(dd,J=9.4,0.8Hz,1H),7.28(dd,J=9.3,1.7Hz,1H),6 .52(s,1H),4.06-3.95(m,2H),3.01-2.83(m,3H),1.99-1.89(m,2H),1.60-1.49(m,2H),1.41(s,9H).

[0234] 4. Synthesis of C7-6

[0235] Dissolve C7-5 (1.23 g, 3.25 mmol) in 8 mL of methanol. Add 4 M hydrochloric acid-dioxane solution (8 mL) under ice-water cooling. React at 50°C for 30 min. After the reaction is complete, concentrate under reduced pressure to obtain 1.3 g of crude product.

[0236] 5. Synthesis of C7-7

[0237] Under ice-water cooling, C7-6 (900 mg, 3.25 mmol) was dissolved in 33 mL of methanol. A 37% methanol solution of formaldehyde (800 mg, 9.76 mmol), acetic acid (0.55 mL, 9.76 mmol), and sodium acetate (295 mg, 3.58 mmol) were added. The reaction was allowed to react at 0°C for 1 h. Sodium cyanoborohydride (410 mg, 6.5 mmol) was then added and stirred for another 1 h. After completion of the reaction, the reaction mixture was quenched with saturated sodium bicarbonate solution under ice-water cooling and extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 650 mg of the product. Ms[M+H] + 294.0. 1H NMR (400MHz, DMSO-d6) δ9.00-8.97(m,1H),7.60(dd,J=9.3,0.8Hz,1H),7.30(dd,J=9.4,1.7Hz,1H),6.53(s,1H),3.11(d,J =11.8Hz,2H),2.97-2.83(m,1H),2.81-2.70(m,1H),2.46(s,3H),2.12-2.00(m,2H),1.91-1.81(m,2H),1.75-1.64(m,1H).

[0238] 6. Synthesis of C7-8

[0239] C7-7 (300 mg, 1.02 mmol), int9 (500 mg, 1.53 mmol), sodium carbonate (325 mg, 3.06 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (37 mg, 0.51 mmol) were dissolved in a mixture of 12 mL of dioxane and 3 mL of water. Under nitrogen, the reaction mixture was heated to 85°C for 1.5 hours. After the reaction was complete, the reaction system was cooled to room temperature and filtered. The filter cake was washed with ethyl acetate, and the filtrate was concentrated under reduced pressure and purified to yield 160 mg of the product. Ms[M+H] + 411.0

[0240] 7. Synthesis of C7-9

[0241] Under ice-water cooling, C7-8 (160 mg, 0.45 mmol) was dissolved in 5 mL of dichloromethane. 2 mL of trifluoroacetic acid was slowly added and stirred at room temperature for 1.5 h. After the reaction was complete, the mixture was concentrated under reduced pressure. The resulting residue was adjusted to pH 8 with saturated sodium bicarbonate and extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 140 mg of crude product.

[0242] 8. Synthesis of C7-10

[0243] Under ice-water cooling, C7-9 (160 mg, 0.45 mmol) was dissolved in methanol (6 mL), and sodium borohydride (34 mg, 0.9 mmol) was slowly added. The reaction solution was stirred at 0°C for 5 min. After the reaction of the raw materials was complete, the reaction was quenched by adding water under ice-water cooling. The reaction was extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 60 mg of crude product. Ms[M+H] + 313.2

[0244] 9. Synthesis of C7-11

[0245] C7-10 (60 mg, 0.19 mmol) was dissolved in 5 mL of N,N-dimethylformamide. INT4 (60 mg, 0.29 mmol), triethylamine (60 mg, 0.57 mmol), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (108 mg, 0.29 mmol) were added sequentially. The system was stirred at room temperature for 5 h. After the reaction of the starting materials was complete, the reaction solution was concentrated under reduced pressure to obtain the crude product. Ms[M+H] + 497.1.

[0246] 10. Synthesis of C7 and C8

[0247] Compound C7-11 was separated and prepared by chiral high performance liquid chromatography to obtain compounds C7 and C8, respectively. The separation conditions were as follows:

[0248] Instrument: Agilent 1260 II

[0249] Column: Phenomenex 5μm Amylose-1 (250 x 30mm)

[0250] Mobile phase: n-hexane: ethanol (0.1% diethylamine) = 3:7

[0251] Flow rate: 15 mL / min, detection wavelength: 254 nm

[0252] Column temperature: 25°C, solvent: ethanol

[0253] Injection concentration: 12 mg / mL, injection volume: 700 μL

[0254] Peak time: 19.04 min (C7), 14.65 min (C8)

[0255] C7: Ms[M+H] + 497.1 1H NMR (400MHz, DMSO-d6) δ8.48(s,1H),7.81(s,1H),7.71(s,1H),7.63(d,J=9.3Hz,1H),7.55- 7.41(m,2H),7.18-7.07(m,1H),6.46(d,J=15.3Hz,3H),5.53(s,1H),3.72-3.60(m,1H),3.1 9-2.98(m,3H),2.88-2.77(m,1H),2.43(s,3H),2.26-2.21(m,4H),2.09-1.96(m,2H),1.89- 1.70(m,4H),1.39-1.31(m,1H),1.26-1.22(m,1H),1.17-1.08(m,2H),0.96(d,J=6.8Hz,3H).

[0256] C8: Ms[M+H] + 497.1 1 H NMR (400MHz, DMSO-d6) δ8.49(s,1H),7.82(s,1H),7.72(d,J=1.7Hz,1H),7.64(d,J=9.2Hz,1H),7.49(d,J=2.3Hz,2H),7.1 9-7.11(m,1H),6.50(s,2H),6.46(s,1H),5.54(s,1H),3.74-3.64(m,1H),3.19-3.06(m,3H),2.90-2.80(m,1H),2.44(s,3 H),2.22(s,3H),2.15(s,1H),2.10-2.01(m,2H),1.90-1.72(m,4H),1.41- 1.33(m,1H),1.27-1.22(m,1H),1.16-1.09(m,2H),0.97(d,J=6.7Hz,3H).

[0257] Example 3

[0258] Compounds of the present invention

[0259] The synthetic route and experimental process are as follows:

[0260] 1. Synthesis of C9-2

[0261] Int6 (680 mg, 1.97 mmol) and C9-1 (400 mg, 1.64 mmol) were dissolved in a mixed solvent consisting of 9 mL of 1,4-dioxane and 3 mL of water. Sodium carbonate (521 mg, 4.92 mmol) and Pd(dppf)Cl2 (59.94 mg, 0.082 mmol) were then added sequentially. Under nitrogen, the reaction mixture was slowly heated to 90°C and stirred for 2 hours. After the raw materials reacted completely, the reaction mixture was cooled to room temperature and diluted with saturated brine. The mixture was then extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 470 mg of the product. Ms[M+H] + 314.1. 1 H NMR (400MHz, DMSO-d6) δ8.44(d,J=1.4Hz,1H),7.96(d,J=2.3Hz,1H),7.64(d,J=9.2Hz,1H),7.04(dd,J=9.1,1.6Hz,1H),6.59(d,J=2.2Hz ,1H),5.5(t,1H),4.65-4.59(m,1H),2.93(dd,J=13.0,6.6Hz,1H),2.22-2.16(m,2H),1.82-1.63(m,2H),1.20-1.14(m,3H),1.01(s,9H).

[0262] 2. Synthesis of C9-3

[0263] C9-2 (450 mg, 1.44 mmol) was dissolved in 5 mL of trifluoroacetic acid and allowed to react at room temperature for 1 h. After the reaction was complete, the reaction system was concentrated under reduced pressure. Saturated sodium bicarbonate solution was added to the resulting residue to adjust the pH to 8. The residue was then extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to yield 310 mg of crude product. Ms[M+H] + 214.1

[0264] 3. Synthesis of C9-4

[0265] Dissolve C9-3 (280 mg, 1.31 mmol) in 10 mL of methanol, add sodium borohydride (99.9 mg, 2.63 mmol), and react in an ice-water bath for 1 h. After the reaction is complete, cool the reaction system to room temperature, concentrate under reduced pressure to remove the solvent, and then dilute the reaction solution with saturated brine and extract three times with dichloromethane. The organic phases are combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 270 mg of the product. Ms[M+H] + 216.1. 1H NMR (400MHz, DMSO-d6) δ8.54(s,1H),7.93(d,J=2.3Hz,1H),7.62(dd,J=9.2,0.9Hz,1H),7.24(dd,J=9.1,1.5Hz,1H),6.54(dd,J=2.3,0.9Hz,1H),3 .64(dd,J=11.0,2.6Hz,1H),2.74-2.71(m,1H),1.85-1.68(m,2H),1.61- 1.54(m,1H),1.52-1.38(m,1H),1.34-1.21(m,2H),1.04(d,J=6.2Hz,3H).

[0266] 4. Synthesis of C9-5

[0267] C9-4 (100 mg, 0.47 mmol) was dissolved in 5 mL of N,N-dimethylformamide, and triethylamine (140.9 mg, 1.39 mmol) and int4 (190.82 mg, 0.94 mmol) were added in sequence. Finally, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (357 mg, 0.94 mmol) was added. The mixture was stirred at 70°C for 5 h. After the reaction of the raw materials was complete, the reaction system was cooled to room temperature, the solvent DMF was evaporated under reduced pressure, and ethyl acetate was added to dilute the mixture. The mixture was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 80 mg of the product after purification.

[0268] 5. Synthesis of C9 and C10

[0269] Compound C9-5 was separated and prepared by chiral high performance liquid chromatography to obtain compounds C9 and C10, respectively. The separation conditions were as follows:

[0270] Instrument: Agilent 1260 II

[0271] Column: Phenomenex 5μm Cellulose-4(250 X 21.2mm)

[0272] Mobile phase: n-hexane:ethanol = 40:60

[0273] Flow rate: 15 mL / min, detection wavelength: 254 nm

[0274] Column temperature: 25°C, solvent: isopropanol

[0275] Injection concentration: 15 mg / mL, injection volume: 600 μL

[0276] Run time: 34 minutes

[0277] Peak time: 17.08 min (C9), 27.77 min (C10)

[0278] C9: Ms[M+H] + 401.2 1H NMR (400MHz, DMSO-d6) δ8.8(s,1H),8.63(s,1H),7.95(d,J=23.1Hz,2H),7.69(d,J=9.3Hz,1H),7.25(d,J=9.3Hz,2H),6.58(s,1H),5.82(d,J=48 .7Hz,2H),4.23(s,1H),2.61(s,1H),2.29(s,3H),1.88(s,2H),1.69(d,J =43.1Hz,2H),1.48(d,J=12.5Hz,1H),1.2(s,1H),0.84(d,J=6.7Hz,3H).

[0279] C10: Ms[M+H] + 401.2 1 H NMR (400MHz, DMSO-d6) δ8.86(s,1H),8.63(s,1H),8.16-7.86(m,2H),7.77-7.40(m,2H),7.25(d,J=9.1Hz,1H),6.58(s,1H),5.82(d,J=46.4H z,2H),4.18(s,1H),2.61(s,1H),2.3(s,3H),1.87(d,J=10.9Hz,2H),1.69(d,J=42.2Hz,2H),1.48(s,1H),1.23(s,1H),0.84(d,J=6.7Hz,3H).

[0280] Example 4

[0281] Compounds of the present invention

[0282] The synthetic route and experimental process are as follows:

[0283] 1. Synthesis of C11-2

[0284] Compound C11-1 (15 g, 49.67 mmol) was dissolved in 150 mL of anhydrous tetrahydrofuran. A 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran (53 mL, 52.65 mmol) was slowly added under ice-water cooling. Stirring was continued for 15 min, maintaining the temperature. Water was added to quench the reaction. The reaction mixture was stirred and warmed to room temperature. The mixture was then extracted three times with methyl tert-butyl ether. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified to yield the crude product, which was directly dissolved in 150 mL of N,N-dimethylformamide for the next reaction.

[0285] 2. Synthesis of C11-4

[0286] The DMF solution of C11-2 obtained in the previous step was cooled in an ice-water bath, and sodium hydride (3 g, 74.5 mmol) with a content of 60% was added. Under nitrogen protection, the temperature was maintained and stirring was continued for 30 min. Then, 100 mL of DMF solution of C11-3 (17.37 g, 74.5 mmol) was added dropwise. The reaction solution was heated to room temperature and stirred for 3 h. After that, water was added to quench the reaction. The reaction was extracted three times with methyl tert-butyl ether. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified to obtain 4.18 g of the product. 1 H NMR (400MHz, DMSO-d6) δ6.74(t,J=2.2Hz,1H),6.64(t,J=2.6Hz,1H),6.02(s,2H),5.93(dd,J=2.9,2.0Hz,1H).

[0287] 3. Synthesis of C11-6

[0288] C11-4 (4.18 g, 26.13 mmol) was dissolved in 40 mL of glacial acetic acid, and C11-5 (3.1 g, 31.35 mmol) was slowly added dropwise. The reaction mixture was stirred at 25°C for 20 h. After completion, the reaction was quenched with water and extracted three times with ethyl acetate. The combined organic phases were cooled in an ice-water bath and adjusted to pH 8 with saturated aqueous sodium bicarbonate. The phases were separated, and the organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified to yield 270 mg of the product. 1 H NMR (400MHz, DMSO-d6) δ8.20(dd,J=4.4,1.7Hz,1H),8.06(dd,J=1.7,0.6Hz,1H),7.96-7.91(m,1H),6.75(dd,J=9.1,4.4Hz,1H),6.69(d,J=1.7Hz,1H).

[0289] 4. Synthesis of C11-7

[0290] C11-6 (270 mg, 1.38 mmol), int9 (667 mg, 2.07 mmol), sodium carbonate (438 mg, 4.14 mmol), and bis(triphenylphosphine)palladium dichloride (98 mg, 0.14 mmol) were added to a mixture of 27 mL of ethylene glycol dimethyl ether and 6.5 mL of water. Under nitrogen, the reaction mixture was heated to 53°C for 1 hour. After the reaction, the reaction system was cooled to room temperature and filtered. The filter cake was washed with ethyl acetate, and the filtrate was concentrated under reduced pressure and purified to obtain 180 mg of the product. Ms[M+H] + 314.2. 1 H NMR (400MHz, DMSO-d6) δ8.06(dd,J=4.4,1.7Hz,1H),7.86(dd,J=8.9,1.7Hz,1H),7.73(d,J=1.7Hz,1H),6.60(dd,J=9.0,4.4Hz,1H),6.43(d,J=1 .7Hz,1H),5.46(t,J=3.6Hz,1H),3.89-3.82(m,1H),3.06-2.96(m,1H),2 .43-2.33(m,1H),1.94-1.78(m,2H),1.07(s,9H),0.96(d,J=6.4Hz,3H).

[0291] 5. Synthesis of C11-8

[0292] Under ice-water cooling, C11-7 (180 mg, 0.57 mmol) was dissolved in 5 mL of dichloromethane. 2 mL of trifluoroacetic acid was slowly added, and the reaction mixture was stirred at room temperature for 2 h. After the reaction was complete, the solvent was evaporated under reduced pressure. The resulting residue was adjusted to pH 8 with saturated sodium bicarbonate solution and then extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to yield 140 mg of crude product. Ms[M+H] + 214.1

[0293] 6. Synthesis of C11-9

[0294] Under ice-water cooling, C11-8 (140 mg, 0.66 mmol) was dissolved in 6 mL of methanol. Sodium borohydride (50 mg, 1.31 mmol) was added portionwise, and the reaction mixture was stirred at 0°C for 5 min. After the reaction of the starting materials was complete, the mixture was cooled under ice-water cooling and quenched with water. The reaction mixture was extracted three times with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and purified to obtain 110 mg of crude product. Ms[M+H] + 216.1 1H NMR (400MHz, DMSO-d6) δ8.09 (dd, J=4.4, 1.8Hz, 1H), 7.88 (dd, J=9.0, 1.8Hz, 1H),7.79(s,1H),6.66-6.57(m,1H),6.51(s,1H),3.79-3.70(m,1H),3.09-3 .00(m,1H),2.35(t,J=11.4Hz,1H),1.97-1.89(m,1H),1.87-1.78(m,1H),1. 63-1.52(m,1H),1.55-1.43(m,1H),1.23-1.09(m,1H),0.86(d,J=6.6Hz,3H).

[0295] 6. Synthesis of C11-10

[0296] C1-9 (60 mg, 0.28 mmol) was dissolved in 5 mL of N,N-dimethylformamide. Int1 (85 mg, 0.41 mmol), triethylamine (85 mg, 0.84 mmol), and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (155 mg, 0.41 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 3 h. After the reaction of the starting materials was complete, the reaction mixture was concentrated under reduced pressure and purified to obtain the crude compound.

[0297] 7. Synthesis of C11 and C12

[0298] Compound C11-10 was separated and prepared by chiral high performance liquid chromatography to obtain compounds C11 and C12, respectively.

[0299] The separation conditions are as follows:

[0300] Instrument: Agilent 1260 II

[0301] Column: Phenomenex 5μm Amylose-1 (250 x 21.2mm)

[0302] Mobile phase: n-hexane: ethanol (0.1% EDA) = 2:8

[0303] Flow rate: 15 mL / min, detection wavelength: 254 nm

[0304] Column temperature: 25°C, solvent: isopropanol: methanol = 2:1

[0305] Injection concentration: 2 mg / mL, injection volume: 3600 μL

[0306] Peak time: 20.7 min (C11), 51.0 min (C12)

[0307] C11: Ms[M+H] + 400.2. 1 H NMR (400MHz, DMSO-d6) δ8.13(dd,J=4.4,1.7Hz,1H),7.92(dd,J=9.0,1.8Hz,1H),7.81(d,J=5.5Hz,2H),7.72(s,1H),7.52-7.45(m,2H),6. 68-6.63(m,1H),6.50-6.42(m,3H),3.21-3.06(m,1H),2.21(s,3H),2 .18-2.05(m,2H),1.85-1.72(m,2H),1.45-1.20(m,3H),1.00(d,3H).

[0308] C12: Ms[M+H] + 400.2. 1 H NMR (400MHz, DMSO-d6) δ8.13(dd,J=4.4,1.7Hz,1H),7.92(dd,J=9.0,1.8Hz,1H),7.81(d,J=5.6Hz,2H),7.72(s,1H),7.53-7.44(m,2H),6.69-6.6 3(m,1H),6.50-6.42(m,3H),3.23-3.11(m,1H),2.24-2.18(m,3H),2.18- 2.03(m,2H),1.86-1.71(m,2H),1.43-1.20(m,3H),1.00(d,J=6.3Hz,3H).

[0309] The above synthesis method was used to synthesize the compounds in the following table:

[0310] Example 5

[0311] Compounds of the present invention

[0312] The synthetic route and experimental process are as follows:

[0313] 1. Synthesis of C17-2

[0314] Dissolve 3-methoxypyridazine (15.5 g, 0.14 mol) in 280 mL of methanol. Add dimethyl butynedioate (79.0 g, 0.56 mol) dropwise under ice-water cooling. After addition is complete, warm to room temperature and stir for 27 hours. After the reaction is complete, cool the reaction mixture to -20°C, filter, and wash the filter cake with cold methanol. Dry the filter cake to obtain 21.17 g of product. Ms[M+H] + 323.2

[0315] 2. Synthesis of C17-3

[0316] C17-2 (23.74 g, 73.73 mmol) was dissolved in a mixed solvent consisting of 240 mL of tetrahydrofuran and 240 mL of water. Potassium hydroxide (41.44 g, 0.74 mol) was added under ice-water cooling. The reaction mixture was then heated to 80°C and stirred for 4 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, concentrated under reduced pressure, and diluted with water until clear. Concentrated hydrochloric acid was added under ice-water cooling to adjust the pH to 1, and the mixture was filtered. The filter cake was washed with water and dried under vacuum to yield 21.36 g of product. Ms[M+H] + 281.0

[0317] 3. Synthesis of C17-4

[0318] Dissolve C17-3 (21.36 g, 76.28 mmol) in 240 mL of concentrated hydrochloric acid, then heat the reaction mixture to 110°C and stir for 4 hours. After the reaction is complete, cool to room temperature, filter, and wash the filter cake with water before vacuum drying to yield 14.15 g of product. Ms[M+H] + 193.0. 1 H NMR (400MHz, DMSO-d6) δ12.34(s,1H),7.99(dd,J=1.8,0.6Hz,1H),7.92(d,J=9.6Hz,1H),6.82(d,J=1.8Hz,1H),6.46(d,J=9.6Hz,1H),3.90(s,3H).

[0319] 4. Synthesis of C17-5

[0320] Under nitrogen protection and ice-water bath cooling, C17-4 (14.15 g, 73.69 mmol) was dissolved in 100 mL of anhydrous tetrahydrofuran solution and slowly added dropwise to a suspension of lithium aluminum hydride (5.60 g, 147.39 mmol) in tetrahydrofuran (180 mL). The reaction was stirred at room temperature for 4 hours. After the reaction, a large amount of anhydrous sodium sulfate was added under ice-water bath cooling, and the reaction was quenched with water. The reaction was stirred for 30 minutes, filtered, and the filtrate was concentrated under reduced pressure and purified to obtain 7.07 g of product. Ms [M+H] + 178.0

[0321] 5. Synthesis of C17-6

[0322] C17-5 (1.5 g, 8.43 mmol) was dissolved in 20 mL of anhydrous dichloromethane, and Dess-Martin periodinane (5.36 g, 12.64 mmol) was added. The reaction was stirred at room temperature for 3 hours. After completion of the reaction, saturated sodium bicarbonate solution was added to quench the reaction. After extraction with dichloromethane three times, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to obtain 504 mg of the product. Ms[M+H] + 176.0

[0323] 6. Synthesis of C17-7

[0324] Under nitrogen protection and ice-water cooling, C17-6 (504 mg, 2.86 mmol) was dissolved in 10 mL of anhydrous dichloromethane. Int8 (1.08 g, 2.86 mmol) and oven-dried 4A molecular sieve powder (286 mg, 100 mg / mmol) were added. The reaction solution was stirred at room temperature for 2 h and monitored by TLC. After completion of the reaction, the solution was filtered and the filtrate was concentrated under reduced pressure to obtain 1.58 g of crude product, which was used directly in the next step without purification.

[0325] 7. Synthesis of C17-8

[0326] Under nitrogen, oven-dried anhydrous copper trifluoromethanesulfonate (1.03 g, 2.86 mmol) was suspended in 12 mL of hexafluoroisopropanol. 2,6-Lutidine (306 mg, 2.86 mmol) was added and stirred at room temperature for 1 hour, resulting in a blue turbid solution. A solution of C17-7 in anhydrous dichloromethane (10 mL) was then added dropwise to the reaction mixture, which was stirred at room temperature for 8 hours. After completion of the reaction, ammonia was added to quench the reaction, and the mixture was extracted three times with dichloromethane. The combined dichloromethane phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 440 mg of the product. Ms[M+H] + 248.1

[0327] 8. Synthesis of C17-9

[0328] C17-8 (327 mg, 1.32 mmol) and int4 (403 mg, 1.98 mmol) were dissolved in 8 mL of anhydrous N,N-dimethylformamide. Triethylamine (0.55 mL, 3.96 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (752 mg, 1.98 mmol) were added sequentially at room temperature. The reaction mixture was stirred at 70°C for 3 h. After completion of the reaction, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 304 mg of the product. Ms[M+H] +433.2. 1 H NMR (400MHz, DMSO-d6) δ8.77(s,1H),7.92(d,J=14.0Hz,2H),7.81(d,J=9.4Hz,1H),7.58(s,1H),6.85(s,2H),6.44(d,J=22.0Hz,1H), 6.32(d,J=9.5Hz,1H),5.72(s,1H),4.54(d,J=11.9Hz,1H),4.18(s,1H),3.87(s,4H),3.68(s,2H),2.27(s,3H),0.92(d,J=6.9Hz,3H).

[0329] 9. Synthesis of C17-10

[0330] C17-9 (456 mg, 1.06 mmol) was dissolved in 10 mL of N-methylpyrrolidone. n-Dodecanethiol (1.07 g, 5.30 mmol) was added dropwise at room temperature. After the addition was complete, sodium ethanethiolate (445 mg, 5.30 mmol) was added and the temperature was raised to 100°C and stirred for 3 hours. After the reaction, the reaction solution was cooled to room temperature and quenched with saturated ammonium chloride solution. The mixture was extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, evaporated to dryness under reduced pressure, and purified to yield 272 mg of the product. Ms[M+H] + 419.0

[0331] 10. Synthesis of C17-11

[0332] C17-10 (143 mg, 0.34 mmol) was dissolved in 3 mL of anhydrous N,N-dimethylformamide, and triethylamine (0.14 mL, 1.02 mol) was added. N-phenylbis(trifluoromethanesulfonyl)imide (153 mg, 0.43 mol) was then added under ice-water cooling. The mixture was warmed to room temperature and stirred for 1 hour. After the reaction, water was added dropwise under ice-water cooling to quench the reaction. The mixture was extracted three times with ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, evaporated to dryness under reduced pressure, and purified to yield 187 mg of the product. Ms[M+H] + 551.0

[0333] 11. Synthesis of C17-12

[0334] C17-11 (187 mg, 0.34 mmol) was dissolved in a mixed solvent consisting of 8 mL of dioxane and 1.6 mL of water. Int9 (152 mg, 0.68 mmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (25 mg, 0.03 mmol), and sodium carbonate (108 mg, 1.02 mmol) were added sequentially. Under nitrogen, the reaction solution was heated to 90°C and stirred for 3 hours. After the reaction, the mixture was cooled to room temperature, quenched with water, and extracted three times with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, evaporated to dryness under reduced pressure, and purified to obtain 142 mg of the product. Ms[M+H] + 498.0. 1 H NMR (400MHz, DMSO-d6) δ8.77(s,1H),7.90(s,2H),7.88-7.57(m,2H),7.01(d,J=9.5Hz,1H),6.87(s,2H),6.62(s,1H),6.53(s,1H),5.76(s ,1H),4.58(s,1H),3.95-3.79(m,1H),3.69(s,2H),3.07(d,J=3.5Hz,2H),2.65-2.51(m,6H),2.28(d,J=7.1Hz,6H),0.91(d,J=7.0Hz,3H).

[0335] 12. Synthesis of C17

[0336] C17-12 (132 mg, 0.27 mmol) was dissolved in 5 mL of methanol, and wet palladium carbon (40 mg, 30 mol%) with a palladium content of 10% was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 18 hours. After the reaction, the reaction solution was filtered through celite, the filter cake was washed with methanol, and the filtrate was concentrated under reduced pressure and purified to obtain 18 mg of the product. Ms[M+H] + 500.0. 1 H NMR (400MHz, DMSO-d6) δ8.77(s,1H),7.95(s,1H),7.90(s,1H),7.82(d,J=9.1Hz,1H ),7.71(s,1H),6.86(s,2H),6.63(d,J=9.3Hz,1H),6.50(s,1H),5.76(s,1H),4.56( s,1H),3.86(d,J=11.8Hz,1H),3.69(s,2H),2.86(d,J=10.8Hz,2H),2.51(s,2H),2. 27(s,3H),2.19(s,3H),2.05-1.88(m,2H),1.86-1.63(m,4H),0.91(d,J=7.0Hz,3H).

[0337] The above synthesis method was used to synthesize the compounds in the following table:

[0338] Example 6

[0339] Compounds of the present invention

[0340] The synthetic route and experimental process are as follows:

[0341] 1. Synthesis of C33-2

[0342] Under nitrogen protection, int7 (834 mg, 2.20 mmol) was dissolved in 10 mL of anhydrous dichloromethane, and 1,3-benzothiazole-5-carboxaldehyde (359 mg, 2.20 mmol) and oven-dried 4A molecular sieve powder (220 mg, 100 mg / mmol) were added. The reaction solution was stirred at room temperature for 2 h. After TLC detection and completion of the reaction, the solution was filtered and the filtrate was concentrated under reduced pressure to obtain 1.15 g of the product.

[0343] 2. Synthesis of C33-3

[0344] Under nitrogen, oven-dried anhydrous copper trifluoromethanesulfonate (795 mg, 2.20 mmol) was suspended in 8.80 mL of hexafluoroisopropanol. 2,6-Lutidine (235 mg, 2.20 mmol) was added and stirred at room temperature for 1 hour, resulting in a blue-green turbid solution. A solution of C33-2 (1.15 g, 2.20 mmol) in anhydrous dichloromethane (10 mL) was then added dropwise to the reaction solution, which was stirred at room temperature for 18 hours. After completion of the reaction, ammonia was added to quench the reaction, and the product was extracted three times with dichloromethane. The combined dichloromethane phases were washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified to yield 417 mg of the product. Ms[M+H] + 235.0. 1H NMR(400MHz,Chloroform-d)δ9.01(s,1H),8.18(d,J=1.6Hz,1H),7.92(d,J=8.3Hz,1H),7.51(dd,J=8.4,1.6Hz,1H),4.07(dd,J=10.2,3.2Hz,1H ),3.93(dd,J=11.2,3.2Hz,1H),3.78-3.71(m,1H),3.53(t,J=10.7Hz,1H),3.10(dd,J=11.7,2.4Hz,1H),2.80(dd,J=11.6,10.1Hz,1H),1.22(d, J=6.3Hz,3H).

[0345] 3. Synthesis of C33

[0346] C33-3 (117 mg, 0.50 mmol) and int1 (131 mg, 0.65 mmol) were dissolved in 4 mL of ultra-dry N,N-dimethylformamide. Triethylamine (101 mg, 2.0 mmol) was added at room temperature, followed by portionwise addition of 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate (390 mg, 0.75 mmol). The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the mixture was diluted with water and extracted three times with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Methanol was added for half an hour, filtered, and the filter cake was dried under vacuum and purified to yield 38 mg of the product. Ms[M+H] + 419.1. 1 H NMR(400MHz,DMSO-d6)δ9.41(s,1H),8.21-8.11(m,2H),7.80(s,1H),7.75(d, J=1.7Hz,1H),7.55(dd,J=8.4,1.7Hz,1H),7.53-7.43(m,2H),6.50(s,2H),5.3 7(t,J=4.6Hz,1H),4.18(dd,J=12.4,4.4Hz,1H),4.11-3.96(m,2H),3.66-3.5 6(m,1H),3.50(d,J=13.5Hz,1H),2.21(d,J=1.1Hz,3H),1.19(d,J=6.5Hz,3H).

[0347] Compound C34 was synthesized using the same synthetic method as shown below:

[0348] C34: Ms[M+H] + 402.1. 1H NMR (400MHz, DMSO-d6) δ8.70(t,1H),8.00(d,J=2.3Hz,1H),7.80(s,1H),7.75(d,J=1.7Hz,1H),7 .70(dd,J=9.2,0.9Hz,1H),7.55-7.39(m,2H),7.25(dd,J=9.2,1.6Hz,1H),6.60(dd,J=2.3,0.9Hz ,1H),6.51(s,2H),5.29(t,J=4.4Hz,1H),4.15(dd,J=12.4,4.3Hz,1H),4.09-3.98(m,2H),3.58(d d,J=13.7,4.1Hz,1H),3.44(dd,J=13.6,3.2Hz,1H),2.21(d,J=1.1Hz,3H),1.18(d,J=6.5Hz,3H).

[0349] Cell proliferation inhibition assay

[0350] 1. Experimental Materials

[0351] 2. Experimental Plan

[0352] 1. Cell plating

[0353] a) Preparation of cell suspension

[0354] b) removing the culture medium from the culture flask;

[0355] c) Rinse the cells once with PBS;

[0356] d) adding trypsin for digestion and collecting by centrifugation;

[0357] e) Resuspend in culture medium, count and adjust to the appropriate concentration.

[0358] f) Add 100 μL of the cell suspension to each well of a 96-well plate, placing one plate for each cell type. Culture overnight in a 37°C, 5% CO2 incubator.

[0359] 2. Compound treatment

[0360] Compound dilution

[0361] a) Prepare a serial dilution of the test compound: Prepare a 10 mM stock solution. Dissolve 2.5 μL of the stock solution in 497.5 μL of DMSO-free culture medium. Perform a 4-fold serial dilution in 0.1% DMSO culture medium for a total of 9 concentrations. The compound concentrations after dilution are as follows:

[0362] 50000nM, 12500nM, 3125nM, 781.25nM, 195.31nM, 48.82nM, 12.2nM, 3.05nM, 0.76nM

[0363] b) After thorough mixing, add 25 μL of compound solution to each well containing 100 μL of cells, using three replicates for each concentration. The final compound concentrations are as follows:

[0364] 10000nM, 2500nM, 625nM, 156.25nM, 39.06nM, 9.77nM, 2.44nM, 0.61nM, 0.15nM

[0365] c) Transfer the cells to an incubator and incubate for 3 days. For adherent cells, change the medium again, aspirate the supernatant, add 100 μL of culture medium to each well, and then add 25 μL of compound solution according to the compound dilution method above. Resuspend the cells and add the compound solution of equal concentration.

[0366] d) Transfer the cells to an incubator and incubate for 4 days.

[0367] 3. CTG test

[0368] a) Remove the cell culture plate and add 25 μL CTG to a 96-well plate. Shake at room temperature for 10 minutes and read the plate.

[0369] 4. Data Analysis

[0370] The following formula was used to calculate the cell survival rate (%Cell Survival):

[0371] %Cell Survival=100%×(OD_Sample-OD_LCave) / (OD_HC-OD_LCave)

[0372] OD_HC: 0.1‰ DMSO control group cell reading

[0373] OD_Sample: Cell readout after compound addition

[0374] OD_LC: Blank culture medium reading

[0375] Analyzed by Prizm: Dose-response-Inhibition-Log(inhibitor) vs response(three parameters for the best fit).

[0376] The results of the cell proliferation inhibition test are shown in Table 1 below.

[0377] Table 1

[0378] A stands for IC 50 ≤100nM; B means 100nM<IC 50 ≤1000nM; C means 1000nM<IC 50 ≤5000nM; D means 5000nM<IC 50

[0379] The experimental results showed that the Example compounds had no obvious inhibitory effect on the non-MTAP-deficient cell line HCC70, but had better activity on the MTAP-deficient cell line LN-18, demonstrating good selectivity of the compounds.

[0380] Enzyme activity test

[0381] Reagents and consumables

[0382] Prepare the compound:

[0383] Prepare the compounds according to the experimental protocols in the table below.

[0384] Experimental steps:

[0385] a) The drug is diluted to the reference concentration and the diluted solution is used as the first point. The dilution is repeated 3 times at a time, for a total of 10 + 0 points.

[0386] b) Transfer 20 nL of compound to a 384-well plate with 2 replicate wells per column. Centrifuge the 384-well plate at 1000 rpm.

[0387] c) Add 2 μL of PRMT5 / MEP50 and MTA solution to each well and incubate at 25°C for 15 min.

[0388] d) Add 2 μL of Bio-H4(1-21) and SAM solution to each well and incubate at 25°C for 180 min.

[0389] e) Add 1 μL 5X MTase-Glo to each well TM Reagents, 384 plates were centrifuged at 1000 rpm.

[0390] f) Incubate at 25°C for 30 minutes.

[0391] g) Add 5 μL of MTase-Glo™ detection solution to each well and centrifuge the plate at 1000 rpm.

[0392] h) Incubate at 25°C for 30 minutes.

[0393] i) Measure luminescence using a plate-reading luminometer.

[0394] Data Analysis:

[0395] The IC50 of the compound was fitted by the nonlinear regression equation:

[0396] %inh=100%-(cmpds-Low control) / (Low control-high control)*100%

[0397] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*Hillslope))

[0398] X: Log value of compound concentration

[0399] Y: Ratio 665 / 615nm

[0400] Top and Bottom: Plateau with the same units as Y

[0401] LogIC50: same unit as X

[0402] Hillslop: Slope factor or slope

[0403] The results of the enzyme activity test are shown in the following table.

[0404] Table 2

[0405] A stands for IC 50 ≤10nM; B means 10nM<IC 50 ≤50nM; C means 50nM<IC 50 ≤500nM; D means 500nM<IC 50 ND: Not Detected

[0406] The experimental results show that at high concentrations of MTA, the compound of this patent exhibits good inhibitory activity against the PRMT5.MTP complex and exhibits good selectivity compared with the control at normal concentrations of MTA.

[0407] The present invention provides a series of compounds with excellent PRMT5 activity and selectivity. The series of compounds have good inhibitory effect and selectivity on MTAP-deficient cells and have broad application prospects.

[0408] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound, characterized in that The compound is a compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, in: R is selected from the following group: H, -NH2, C 1-3 Alkyl, -OC 1-3 Alkyl, C 1-3 Fluorinated alkyl, -OC 1-3 Fluorinated alkyl; R1 is selected from the following groups: substituted or unsubstituted: monocyclic group A, bicyclic group B; the monocyclic group A is selected from the following group: C 3-8 Cycloalkyl, C 5-8 Aryl, 3-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, 5-8 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S; the bicyclic group B is selected from the following group: C 5-12 Cycloalkyl, C 8-12 aryl, 5-12 membered heterocyclic radical containing 1-4 heteroatoms selected from N, O or S, 8-12 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S; wherein, when substituted, the substitutions are each independently replaced by R a1 replace; R2 is selected from the group consisting of H, halogen, -CN, C 1-6 Alkyl, -OR a2 ; or R2 together with the C to which it is connected forms C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S; wherein the alkyl, cycloalkyl, heterocycloalkyl is optionally substituted by a substituent selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, C 1-3 Fluoroalkoxy, C 3-5 Cycloalkyl, 4-6 membered heterocycloalkyl containing 1-2 heteroatoms selected from N, O or S; Each R3 is independently selected from the group consisting of H, deuterium, =O, halogen, -CN, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, -OR a3 、-N(R a3 ) 2, wherein the alkyl, heteroalkyl is optionally substituted by a substituent selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, C 1-3 Fluoroalkoxy; Alternatively, two R3's and the atoms to which they are attached, or R3's and the group attached to the nitrogen heterocycle to which they are attached, together form a 3-10 membered carbocyclic or heterocyclic ring, and the carbocyclic or heterocyclic ring and the nitrogen heterocycle form a bridged ring, a fused ring, or a spirocyclic ring; R4 is selected from the group consisting of H, deuterium, halogen, -CN, C 1-3 Alkyl, C 2-6 Alkynyl, C 3-5 Cycloalkyl, 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S, -OR a4 、-C(=O)N(R a4 )2、-S(=O)2N(R a4 ) 2, wherein the alkyl, cycloalkyl, heterocycloalkyl is optionally substituted by a group selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Fluorinated alkyl; R5 is selected from the group consisting of H, deuterium, halogen, -CN, C 1-3 Alkyl, C 3-5 Cycloalkyl, 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S, -OR a5 , wherein the alkyl, cycloalkyl, heterocycloalkyl is optionally substituted by a group selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Fluorinated alkyl; Each x1, x2, x3, x4 is independently selected from the following group: O, C(R a6 ) m 、N(R a6 ) m ; Each R a2 、R a3 、R a4 、R a5 Independently selected from the group consisting of H, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-7 membered heterocyclic group containing 1-2 heteroatoms selected from N, O or S, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclic group is optionally substituted by 1, 2 or 3 R b1 replace; Each R b1 Independently selected from the group consisting of: =O, halogen, -CN, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 1-6 Haloalkyl, -OR c1 、-N(R c1 )2; Each R c1 Independently selected from the group consisting of H, C 1-6 Alkyl, C 3-6 Cycloalkyl; Each R a1 Independently selected from the group consisting of deuterium, halogen, -CN, =O, -OH, C 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 1-6 Haloalkyl, -LC 3-9 Cycloalkyl, -L-(saturated or partially saturated 3-10 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S), -LC 6-10 Aryl, -L- (5-10 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S), -OL- (3-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O or S), -OR b2 、-N(R b2 )2、-LN(R b2 )2, -C(=O)R b2 、-C(=O)OR b2 、-P(=O)(R b2 )2、-NR b2 C(=O)R b2 、-NR b2 C(=O)OR b2 、-C(=O)N(R b2 )2、-OC(=O)N(R b2 )2、-S(=O)R b2 、-S(=O)2R b2 、-SR b2 、-S(=O)(=NR b2 )R b2 、-NR b2 S(=O)2R b2 、-S(=O)2N(R b2 ) 2, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by a substituent selected from the group consisting of: =O, deuterium, halogen, -CN, -OH, -NH2, -NHC 1-3 Alkyl, -N(C 1-3 Alkyl)2, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, -OC 1-6 Alkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, -OC 1-6 Halogenated alkyl, C 1-6 Haloalkyl, C containing 1-2 heteroatoms selected from N, O or S 1-6 Haloheteroalkyl, -C(=O)Me, -C(=O)NHMe, -NHC(=O)Me; Each R b2 Independently selected from the group consisting of H, C 1-6 Alkyl, C 1-6 Haloalkyl, C substituted with 0-1 =O and containing 1-2 heteroatoms selected from N, O or S 1-6 Heteroalkyl, C 3-9 Cycloalkyl, 3-10 membered heterocyclyl containing 1-4 heteroatoms selected from N, O or S, optionally substituted by =O or -CH3; Each L is independently a bond or C 1-6 Alkylene, wherein the C 1-6 The alkylene group is optionally substituted with a substituent selected from the group consisting of deuterium, halogen, -CN, -OH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluorinated alkyl, C 1-3 Fluoroalkoxy; Each R a6 Independently selected from the group consisting of H, deuterium, halogen, -CN, C 1-3 Alkyl, C 1-3 Fluorinated alkyl, C 1-3 Alkoxy, C 1-3 Fluoroalkoxy; Each m is independently selected from the following group: 0, 1, 2; n is selected from the following group: 0, 1, 2, 3.

2. The compound according to claim 1, wherein The compound has a structure selected from the group consisting of: wherein R1, R2, R3, R4, R5, x1, x2, x3, x4, R, and n are as defined in claim 1.

3. The compound according to claim 2, wherein The compound has a structure selected from the group consisting of: wherein R1, R2, R3, R4, and x2 are as defined in claim 1.

4. The compound according to claim 3, wherein R1 is selected from the substituted or unsubstituted bicyclic group B, wherein, when substituted, the substitutions are each independently a1 replace; The compound has a structure selected from the group consisting of: Among them, R2, R3, R4, R a1 , x2 as defined in claim 1.

5. The compound according to claim 1, wherein The monocyclic group A has a structure selected from the group consisting of: The bicyclic group B has a structure selected from the group consisting of:

6. The compound according to claim 1, wherein R a1 The cycloalkyl group has a structure selected from the group consisting of: R a1 The heterocyclic group has a structure selected from the following group: R a1 The heteroaryl group has a structure selected from the group consisting of:

7. The compound according to claim 1, wherein R is selected from the following group: H, -NH2, C 1-3 Alkyl, -OC 1-3 alkyl; R2 is selected from the following group: H, C 1-6 Alkyl, -OR a2 ; or R2 together with the C to which it is connected forms C 3-6 Cycloalkyl or 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S; R a2 As defined in claim 1; R3 is selected from the group consisting of H, halogen, C 1-6 Alkyl; or, two R3 and the atoms to which they are attached or R3 and the group attached to the nitrogen heterocycle to which they are attached together form a 3-10 membered carbocyclic or heterocyclic ring; R4 is selected from the group consisting of halogen, -CN, C 1-3 Alkyl, C 2-6 Alkynyl, C 3-5 Cycloalkyl, 3-6 membered heterocycloalkyl containing 1-4 heteroatoms selected from N, O or S, -OR a4 、-C(=O)N(R a4 )2、-S(=O)2N(R a4 )2; R a4 As defined in claim 1; R5 is selected from the group consisting of H, halogen, -CN, C 1-3 alkyl.

8. The compound according to claim 1, wherein The compound is selected from the group consisting of:

9. A pharmaceutical composition, characterized in that The invention comprises a therapeutically effective amount of one or more compounds according to claim 1 and a pharmaceutically acceptable carrier.

10. Use of the compound according to claim 1, characterized in that: Used for preparing drugs for regulating PRMT5 activity or treating PRMT5-related diseases.